BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//IBSAL - ECPv6.18.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://ibsal.es/en/
X-WR-CALDESC:Events for IBSAL
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Helsinki
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20271031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20280326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20281029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250326
DTEND;VALUE=DATE:20300604
DTSTAMP:20251114T074015Z
CREATED:20250304T093623Z
LAST-MODIFIED:20251114T074015Z
UID:10002030-1742947200-1906761599@ibsal.es
SUMMARY:Diverse and responsible health
DESCRIPTION:The project “Diverse and Responsible Health” aims at the scientific dissemination of the IBSAL among the LGTBI+ population of Salamanca. Through a series of workshops scheduled throughout 2025\, various key issues for the health of this group will be addressed\, promoting a gender and diversity perspective in medical and scientific research. \nThese workshops\, led by the Eros Service of Asociación Iguales\, will have the participation of specialized professionals\, IBSAL research staff and collaborating entities. The program includes four sessions with the following topics:  \n\n\n\n\nITS: Why do they always point the finger at us?  – Analysis of sexually transmitted infections in the LGTBI+ population and the need for a person-centered approach.\n\n  \nDate: Wednesday\, March 26\, 2025\, at 7:00 p.m. \nPlace: La Vegatería (C/ Gütenberg\, 13\, 37007 Salamanca) \nIBSAL Researchers: Moncef Belhassen and Virginia Velasco \nFree admission \n  \n \n  \n\nChemSex: an emerging phenomenon or an old acquaintance?  – Study of ChemSex and its impact on health from a community perspective.\n\n  \nMore information coming soon. \n  \n\nLifestyles in queer people – Promotion of healthy habits and analysis of health determinants in the LGTBI+ population.\n\n  \nMore information coming soon. \n  \n\nMental health: how to take better care of ourselves – Minority stress\, discrimination and other barriers that affect the mental health of minorities.\n\n  \nMore information coming soon. \n  \nEach workshop will combine the presentation of specialists in the field with the participation of IBSAL research staff\, bringing scientific research closer to the community. \nThe project has the collaboration of several local entities and is supported by the University of Salamanca\, the City Council of Salamanca and the IBSAL.
URL:https://ibsal.es/en/evento/diverse-and-responsible-health/
LOCATION:La Vegatería\, 13 Gütenberg Street\, Salamanca\, Salamanca\, 37007\, Spain
CATEGORIES:Disclosure
ATTACH;FMTTYPE=image/png:https://ibsal.es/wp-content/uploads/2025/03/Logo-Iguales-Tagline-Color.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260101
DTEND;VALUE=DATE:20280102
DTSTAMP:20251124T061504Z
CREATED:20251124T061504Z
LAST-MODIFIED:20251124T061504Z
UID:10002268-1767225600-1830383999@ibsal.es
SUMMARY:PARTNERSHIP: European Partnership on One Health and Antimicrobial Resistance (OH AMR)
DESCRIPTION:Features\nThe first joint transnational call for proposals from the  EUP OHAMR Partnership on Antimicrobial Resistance\,  titled  “Treatments and Adherence to Treatment Protocols” \nThe goal of this call for proposals is to improve treatment success rates in patients\, animals\, and plants affected by bacterial or fungal infections by offering new treatment options while reducing the risk of resistance development across the various settings of the “One Health” approach . \nThe call for proposals is co-financed by the European Union and involves 37 funding organizations from 28 countries\, with a total estimated budget of more than 31 million euros. \nIn addition\, the following national and regional funding agencies are participating in this call for proposals: the Aragon Institute of Health Sciences (IACS)\, the State Research Agency (AEI)\, and the Carlos III Health Institute (ISCIII). \nRequirements\nProposals must address one of the following topics: \nTopic 1: Identify and develop new combination therapies using existing or innovative antimicrobials\, or antimicrobials in combination with adjunctive therapies\, to extend drug efficacy and combat resistance. \nTopic 2:  Develop  tools and methods to improve adherence to treatment protocols. \nTopic 3: Assess the impact of antimicrobials used in veterinary and agricultural settings on the risk of AMR transmission to humans and the environment\, to inform policies on restricting certain antimicrobials for human use. \n\nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 18\, 2025\n\n\nDeadline for Pre-Proposals\nFebruary 2\, 2026\, (1:00 p.m. CET)\n\n\nNotification of the Results of the Pre-Proposal\nApril 29\, 2026\n\n\nDeadline for full proposals\nJune 17\, 2026\, (1:00 p.m. CET)\n\n\nFinal Funding Recommendation Announced\nOctober 30\, 2026\n\n\nProjects begin\nDecember 2026–April 2027\n\n\n\n  \n 
URL:https://ibsal.es/en/evento/partnership-european-partnership-on-one-health-and-antimicrobial-resistance-oh-amr-2/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260101
DTEND;VALUE=DATE:20280102
DTSTAMP:20251126T071112Z
CREATED:20251126T071112Z
LAST-MODIFIED:20251126T071112Z
UID:10002178-1767225600-1830383999@ibsal.es
SUMMARY:PARTNERSHIP European Partnership for Personalized Medicine (EP PerMed)
DESCRIPTION:Features\nA joint transnational call for proposals has been published by the European Partnership for Personalized Medicine (EP PerMed)\,  Joint Transnational Call (JTC) 2026: Personalized Medicine for Cardiovascular\, Metabolic\, and Kidney Diseases (CARMEN2026) \nThis call for proposals will fund human health research projects on innovative personalized medicine strategies for patients with cardiovascular\, metabolic\, or kidney diseases. Research projects may focus on a single disease or address these conditions in combination.  \nResearch projects that combine a personalized medicine approach with care strategies targeting shared biological pathways or common underlying mechanisms of cardiovascular\, metabolic\, and renal diseases will be viewed favorably. \nThe call for proposals is co-funded by the European Union and involves 39 funding organizations from 27 countries\, with a total estimated budget of over 38 million euros. \nIn addition\, the Carlos III Health Institute (ISCIII) is participating in this call for proposals as the national funding agency. \nRequirements\nProposals should address one or more of the following aspects: \n\nDevelopment and validation of innovative\, personalized therapeutic approaches for cardiovascular\, metabolic\, or kidney diseases through testing in relevant preclinical models (e.g.\, human cell cultures\, organoids\, organs-on-chips\, disease-specific animal models\, or in silico models).\nIdentification and validation of molecular markers/signatures or cutting-edge technologies (see also point 2 below) to monitor treatment response in patients with cardiovascular\, metabolic\, or kidney diseases in order to tailor treatment pathways. This may include the analysis of treatment effectiveness or treatment-related (including those associated with multiple medications) adverse effects\, as well as dose optimization. \nIdentification and validation of stratifying molecular markers or signatures\, or stratifying diagnostic technologies\, for the early prediction of disease risk and the prevention of disease progression or comorbidities in patients with cardiovascular\, metabolic\, or kidney diseases\, thereby delaying the progression to cardiovascular-kidney-metabolic syndrome.\n\n  \nResearch projects that combine a personalized medicine approach with care strategies targeting shared biological pathways or common underlying mechanisms of cardiovascular\, metabolic\, and kidney diseases are welcome. \nProjects funded under this call are also required to include a dedicated work package focusing on the translation or implementation of research outcomes into clinical practice\, with an emphasis on\, for example\, patient outcomes\, patient preferences\, costs\, reimbursement\, education (for healthcare providers\, patients\, and citizens)\, ELSA (ethical\, legal\, and societal aspects)\, or accessibility at the point of care. \nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 25\, 2025\n\n\nDeadline for Pre-Proposals\nFebruary 10\, 2026\, (2:00 p.m. CET)\n\n\nNotification of the Results of the Pre-Proposal\nMay 5\, 2026\n\n\nDeadline for full proposals\nJune 9\, 2026\, (2:00 p.m. CET)\n\n\nRebuttal stage\nMid- to late August 2026\n\n\nNotification of Funding Decisions\nOctober 2026\n\n\n\n  \n 
URL:https://ibsal.es/en/evento/partnership-european-partnership-for-personalized-medicine-ep-permed/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260101
DTEND;VALUE=DATE:20280102
DTSTAMP:20251215T081017Z
CREATED:20251215T081017Z
LAST-MODIFIED:20251215T081017Z
UID:10002206-1767225600-1830383999@ibsal.es
SUMMARY:PARTNERSHIP: Transforming Health and Care Systems (THCS)
DESCRIPTION:Features\nA joint transnational call for proposals has been published by the Transforming Health and Care Systems (THCS) partnership\,  Joint Transnational Call for Proposals (2026) on Access to Care. \nThis call for proposals promotes the coordination and optimization of research and innovation efforts to support the necessary transformation of health and social care systems in Europe and partner countries. Its goal is to fund projects that help ensure equitable access to and appropriate use of health and care services\, providing policymakers and decision-makers with the knowledge and tools needed to reallocate resources effectively.  \nThe projects\, based on existing evidence\, will develop innovative solutions to reduce inequalities in access to care by addressing financial models\, service delivery models\, and integrated and interdisciplinary care programs at all levels of the system. \nThe call for proposals is co-financed by the European Union and involves 32 funding organizations\, with a total estimated budget of more than 35 million euros. \nIn addition\, the Carlos III Health Institute (ISCIII) is participating in this call for proposals as the national funding agency. \nRequirements\nThe aim of the call is to fund research and innovation projects that\, within an ecosystem approach\, contribute to ensuring equitable access to and use of health and care services. Through the funded research and innovation projects\, policymakers and decision-makers should gain the knowledge and tools necessary to implement the reallocation of resources as the health and care system undergoes a transition to address new and ongoing challenges. \nAll proposals would benefit from co-creation with stakeholders\, particularly people from disadvantaged groups. Proposals are encouraged to incorporate elements of the social sciences as part of an interdisciplinary approach.  \nThis call requires collaborative\, transnational research\, innovation\, and evaluation activities. It is mandatory to engage in one or more of the following types of activities: applied research\, implementation research\, piloting\, upscaling\, and/or testing. All projects must demonstrate proof of concept(s)\, validate concepts\, models\, or solutions\, and showcase demonstrations of solutions in relevant health and care ecosystems. The adaptation of already adopted solutions to other settings is also within the scope of this call.   \n  \nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 21\, 2025\n\n\nDeadline for Pre-Proposals\nFebruary 2\, 2026\, (2:00 p.m. CET)\n\n\nCall for Full Proposals\nStarting May 11\, 2026\n\n\nDeadline for full proposals\nJune 30\, 2026\, (2:00 p.m. CET)\n\n\nRebuttal stage\nSeptember 2026\n\n\nNotification of Funding Decisions\nLate October 2026\n\n\n\n  \n 
URL:https://ibsal.es/en/evento/partnership-transforming-health-and-care-systems-thcs/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260101
DTEND;VALUE=DATE:20270101
DTSTAMP:20260112T060813Z
CREATED:20260112T060813Z
LAST-MODIFIED:20260112T060813Z
UID:10002251-1767225600-1798761599@ibsal.es
SUMMARY:Reticular Model of Organization and Community Care for People with Mental Illness
DESCRIPTION:Coeducational Course: “Reticular Model of Organization and Community Care for People with Mental Illness“ \n  \nObjective: \nTo explain how the network-based model for organizing mental health services and facilities works\, with a focus on the coordination of social and health care services and between mental health and primary care. \n  \nSpecific objectives: \n\nBecome familiar with all the health and social care services integrated into the mental health social-health care network under the network model. Describe the operations and objectives of the Assertive Community Treatment Unit. Conduct a study to develop a feasible proposal for implementation in your workplace.\nTo understand the changes introduced by the model to improve the quality of care in the field of mental health. \nIdentify the epistemological and organizational foundations of the model and its implementation in a healthcare region such as Zamora. \nTo lay the groundwork for coordination among distinct care networks—such as social-health\, social\, and health care networks—as well as to define the new roles of workers within these networks.\n\nDate: \nFrom August 1 to December 31\, 2025. \n  \nLocation: \nOnline and the Zamora Mental Health Department. \n  \nEnrollment:   \n  \nRegistration is open throughout the academic year on an individual basis via our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \n  \nPrice: \n50 euros (USAL students\, PhD students\, IBSAL members\, students from developing countries\, primarily in Latin America). \n150 euros (general admission). \n  \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n 
URL:https://ibsal.es/en/evento/reticular-model-of-organization-and-community-care-for-people-with-mental-illness/
LOCATION:Online\, Online
CATEGORIES:Course
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260117
DTEND;VALUE=DATE:20270120
DTSTAMP:20261111T132231Z
CREATED:20251124T120728Z
LAST-MODIFIED:20261111T132231Z
UID:10002252-1768608000-1800403199@ibsal.es
SUMMARY:ERA4HEALTH Partnership
DESCRIPTION:Features\nThe preliminary announcement for the ERA4HEALTH 10th Joint Transnational Call (JTC)  has been published  Nano and advanced technologies for developing diagnostic tools to improve the detection and clinical management of noncommunicable diseases—NanoDiagNCD.  \nThe goal is not simply to develop a new technology: the proposal must demonstrate added value compared to existing diagnostic tools\, for example in terms of sensitivity\, specificity\, accessibility\, cost\, patient comfort\, invasiveness\, or safety. In addition\, aspects such as scalability\, manufacturing\, standardization\, cost-effectiveness\, regulation\, interoperability\, and integration into healthcare systems must be considered from the outset.  \nThe call for proposals is co-funded by the European Union and involves more than 15 funding organizations from over 20 countries\, with a total estimated budget of more than 18 million euros. \nIn addition\, the Carlos III Health Institute (ISCIII) is participating in this call for proposals as the national funding agency. \nRequirements\nThese are transnational consortia consisting of 3–5 eligible partners from at least 3 participating countries. In addition:  \n\nAt least two eligible partners must be from different EU member states or countries associated with Horizon Europe that are participating in the program.\nA maximum of 2 eligible members from the same country.\nThe number of eligible partners could reach 6 or 7 once one or two eligible partners\, respectively\, from Lithuania\, Slovakia\, or Taiwan join the project.\nUp to 2 self-funded collaborators who do not apply for funding are permitted.\n\nParticipants may fall into one of four categories: \nA. Academia\nB. Clinical/public health sector\nC. Enterprises\nD. Operational stakeholders \nIt is important to note that the proposal must include partners applying for funding from at least two of the three categories—A\, B\, and C. In other words\, the consortium must include\, at a minimum\, two of these three types: \nAcademia + the clinical/public health sector + businesses. \nIn addition\, ERA4Health recommends involving Category D stakeholders when relevant to the project. \nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 17\, 2026\n\n\nDeadline for Pre-Proposals\nJanuary 19\, 2027\, (12:00 CET)\n\n\nNotification of the Results of the Pre-Proposal\nApril 14\, 2027\n\n\nDeadline for full proposals\nJune 9\, 2027\, (12:00 CET)\n\n\nRebuttal stage\nAugust 26\, 2027\n\n\nProjects begin\nDecember 2027–May 2028\n\n\n\n  \n 
URL:https://ibsal.es/en/evento/era4health-partnership-2/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260421
DTEND;VALUE=DATE:20270116
DTSTAMP:20260518T124654Z
CREATED:20260518T124654Z
LAST-MODIFIED:20260518T124654Z
UID:10002294-1776729600-1800057599@ibsal.es
SUMMARY:Call for Applications: INVESMIR SEC-CNIC Training Program 2026
DESCRIPTION:Purpose\nThe INVESMIR SEC-CNIC Program aims to supplement the training of medical professionals during their hospital residency by facilitating the development of a research project in the CNIC laboratories under the supervision of a CNIC scientist. \nThis program also aims to establish the necessary connections and partnerships so that\, upon completing their specialization\, these professionals can continue to develop their research projects at their respective hospitals\, with the support of the SEC and the CNIC. \n  \nTerms and Conditions\nA maximum of 10 spots will be awarded for the INVESMIR SEC-CNIC training program in the 2026 call for applications. \nThe potential recipient groups for the CNIC under this program and information regarding their research areas are available at the following link:\nhttps://www.cnic.es/es/investigacion/laboratorios \nInterested individuals must contact the research groups and be accepted into one of them in order to apply.\nIn all cases\, the training stints will be full-time. \nParticipants from hospitals outside the Community of Madrid will have their travel expenses to Madrid covered up to a maximum of 300 € (one round-trip from their usual place of residence; if traveling by public transportation\, it must be in economy class\, in accordance with the CNIC’s travel policy). In addition\, these participants will be reimbursed for accommodation expenses in Madrid up to a maximum of 250 euros per week. Any amounts exceeding the weekly limit will be offset against one another\, provided they do not exceed 1\,000.00 € over a four-week period.   \nAll expenses must be supported by documentation\, including invoices issued in the participant’s name and proof of payments made from their bank account. The documentation must be sent in a single email to programa_formación@cnic.es within 10 calendar days after the end of the stay at the Center. Once the documentation has been reviewed\, the participant will be notified of which supporting documents must be submitted as original hard copies (invoices\, receipts\, or other supporting documents) and mailed to the Center’s address.   \nParticipation in the internship will not entail any type of contractual relationship between the intern and the CNIC. \n  \nDuration and Length of Stay\nThe duration of the stay will be flexible\, ranging from 4 to 6 months\, in accordance with the regulations set forth in the MIR Training Program of the participant’s home hospital.\nStays must take place entirely between June 1\, 2026\, and May 31\, 2027\, except in exceptional circumstances duly authorized by the CNIC and SEC management. \n  \nRequirements\nBe a member of the Spanish Society of Cardiology (SEC).\nBe a medical professional\, of any nationality\, currently in the R3\, R4\, or R5 years of a residency program in Cardiology or Cardiovascular Surgery at a hospital in Spain. \n  \nDeadline and Formalization\nThe call for applications will be open from April 21\, 2026\, through January 15\, 2027.\nApplications must be submitted exclusively through the CNIC online system:\nhttps://www.cnic.es/es/convocatoria/invesmir-sec-cnic\, and the following documentation must be attached: \n\nResume.\nNational Identity Card.\nDocument verifying your personal Social Security number (those issued by mutual insurance companies are not valid).\nA signed authorization from the Academic Committee of the training program at the participant’s home hospital\, expressly stating the dates of the stay.\nLetter of Acceptance from the CNIC Supervising Researcher Responsible for the Stay\nBrief description of the proposed research project for the residency\nCertificate of residence for candidates residing in Spain outside the Community of Madrid.\n\nDocuments must be attached to the form in PDF format. \nFollowing the publication of the call for applications\, applications will be reviewed on the 15th of each month. Each applicant will then be notified by email whether their application has been accepted or\, if applicable\, the reasons for requiring corrections or for exclusion. Applicants in the correction phase may correct the errors that led to the rejection of their application within a maximum period of 5 days\, starting the day after the notification date. The decision regarding admission to or exclusion from the evaluation process will be communicated through the same procedure.    \nElectronic signatures will be used throughout the selection process and the subsequent hiring procedures; therefore\, applicants must have a digital ID (DNIe) or a recognized electronic certificate issued by a registered certification authority (https://sedeaplicaciones.minetur.gob.es/Prestadores/)\, such as the one issued by the National Mint and Stamp Factory. \nTERMS AND CONDITIONS OF THE CALL FOR APPLICATIONS
URL:https://ibsal.es/en/evento/call-for-applications-invesmir-sec-cnic-training-program-2026/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260501
DTEND;VALUE=DATE:20270101
DTSTAMP:20260518T094535Z
CREATED:20260518T094535Z
LAST-MODIFIED:20260518T094535Z
UID:10002280-1777593600-1798761599@ibsal.es
SUMMARY:EATRIS-CONNECCT Knowledge Exchange Program
DESCRIPTION:Features\nThe call for applications for the EATRIS-CONNECT knowledge exchange program offers grants of up to €1\,000 for researchers who wish to spend time at an eligible research institution\, with a focus on improving digital transformation in translational medicine. The program covers travel\, lodging\, and living expenses related to the visit.  \nDigital transformation in translational medicine refers to the use of advanced digital technologies—such as data\, tools\, and services—to develop innovative solutions to unmet medical needs. \nThe call for applications is open to both EATRIS-CONNECT project partners and EATRIS organizations that are not officially part of the consortium. Expenses will be reimbursed upon completion of the visit and submission of the final report.  \nRequirements\nWhat types of exchanges are funded? \nThere are no predefined exchange types\, but some examples include: \n\nDigital Transformation Literacy (DT Literacy): Individual staff exchanges between nodes to facilitate the transfer of knowledge related to digital solutions\, workflows\, and service delivery that support the development of translational medicine.\nWorkshops: group exchange of best practices or collaborative development of digital solutions.\nCollaborative initiatives: sharing experiences and ideas to drive joint digital transformation initiatives.\nOnline or virtual knowledge-sharing sessions: digital seminars\, webinars\, and other virtual events for sharing knowledge.\n\n\n\n\nHow to apply\nYou must submit the “Knowledge Exchange proposal” via this link to the application form. Before submitting it\, please verify your eligibility\, and we recommend that you read the program guide.  \nThere is no deadline for submitting applications.
URL:https://ibsal.es/en/evento/eatris-connecct-knowledge-exchange-program/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260921
DTEND;VALUE=DATE:20261212
DTSTAMP:20261105T080858Z
CREATED:20261028T091518Z
LAST-MODIFIED:20261105T080858Z
UID:10002459-1789948800-1797033599@ibsal.es
SUMMARY:Integrated Services for Infectious Disease Outbreak Research\, ISIDORe—Andes Virus and Andv-Related Hantavirus Research
DESCRIPTION:Features\nThe call for proposals titled “Andes Virus & ANDV-relevant Hantavirus Research” is part of ISIDORe II\, an initiative funded by the European Union’s Horizon Europe program to facilitate access to specialized research infrastructure and services for infectious diseases. \nThe main feature is that it does not provide a financial grant to the researcher or their institution. Instead\, it funds access to specialized scientific services provided by the participating infrastructures\, at no cost to the selected users.  \nProposals must address the Andes virus (ANDV) or research on hantaviruses that is clearly related to it. Research on other hantaviruses without justifying that relationship falls outside the scope of this call for proposals.  \nThree priority areas are established: \n\nEvaluation of treatments and non-vaccine-based prophylaxis. Evaluation and characterization of antiviral candidates\, antibodies\, and other therapeutic or preventive strategies that already have a scientific basis. \nDiagnostics\, assays\, and reference materials. Development or adaptation of assays\, evaluation of sensitivity and specificity\, analytical validation\, reagents\, controls\, and reference materials. \nModels and experimental systems. Use and characterization of models to study pathogenesis\, viral tropism\, host response\, or the evaluation of medical countermeasures. \n\n  \nServices available: \n\n\n\n\nAnalysis: RT-PCR design\, NGS sequencing\, and whole-genome sequencing of ANDV. \n\n\n\n\n\n\nDrug discovery: screening of antiviral compounds\, validation of candidates\, and characterization of monoclonal antibodies. \n\n\n\n\n\n\nCell-based and ex vivo models: human organoids\, lung\, placenta\, and endothelial models\, and antiviral assays. \n\n\n\n\n\n\nIn vivo models: preclinical efficacy studies and animal models\, subject to applicable scientific and ethical requirements. \n\n\n\n\n\n\nImmunomonitoring and structural biology: cellular immunity assays\, protein production and characterization\, and advanced microscopy techniques. \n\n\n\n\n\n\nRegulatory and clinical support: guidance on preparing research studies and addressing ethical or regulatory issues. \n\n\n\n\nThe availability of a service in the general catalog does not guarantee that any use of that service is eligible: it must comply with the priorities and exclusions of this specific call for proposals. \n  \nRequirements\nThe call for proposals is open to researchers from universities\, public research institutions\, public health organizations\, companies\, small and medium-sized enterprises\, and other organizations that conduct research. \nThe main requirements and conditions are: \n\n\n\n\nScientific scope: The proposal must address ANDV or an issue related to another hantavirus whose relevance to ANDV is clearly justified. \n\n\n\n\n\n\nAccess to services: You must request one or more services included in the ISIDORe II catalog. \n\n\n\n\n\n\nTransnational dimension: Horizon Europe’s transnational access (TNA) rules apply. The principal investigator and the majority of users must meet the geographic access conditions with respect to the hosting facility. The location of the service is determined during the process.   \n\n\n\n\n\n\nPriority: Preference will be given to applicants who did not receive funding in the first ISIDORe project. \n\n\n\n\n\n\nEthics and security: Applicable requirements regarding ethics\, biosafety\, bioprotection\, data protection\, and the use of services must be met. \n\n\n\n\n\n\nDissemination: The results must be disseminated\, and ISIDORe’s contribution must be appropriately acknowledged. \n\n\n\n\nAt least 80% of access must benefit users from EU Member States or countries associated with Horizon Europe; up to 20% may be allocated to international users who meet the relevant conditions. \nThe call for proposals guidelines state that the following are not included: \n\n\n\n\nRoutine diagnosis and epidemiological surveillance. \n\n\n\n\n\n\nClinical trials. \n\n\n\n\n\n\nManufacturing and scaling of production processes. \n\n\n\n\n\n\nWide-ranging screening campaigns without a specific hypothesis or need. \n\n\n\n\n\n\nDevelopment of entirely new services that are not available in the current offering. \n\n\n\n\nWe are looking for a specific scientific need that can be addressed through specialized services available at the participating research infrastructures. \nHow to apply\nThe application consists of two phases: a preliminary application and a full application. It is important to review the full text of the call for proposals to verify scientific relevance and eligibility criteria. Applications are submitted through the application management system (Access Management System\, AMS).   \nThis link takes you to the services catalog\, where you can view available infrastructure and services. \nThe deadline for the complete application is December 11\, 2026. The preliminary application is submitted first\, and then the ISIDORe team provides instructions on how to complete the application.
URL:https://ibsal.es/en/evento/integrated-services-for-infectious-disease-outbreak-research-isidore-andes-virus-and-andv-related-hantavirus-research/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260921
DTEND;VALUE=DATE:20261231
DTSTAMP:20261002T082542Z
CREATED:20261002T082542Z
LAST-MODIFIED:20261002T082542Z
UID:10002428-1789948800-1798675199@ibsal.es
SUMMARY:Scientific and Technical Sessions for Senior Clinical and Biomedical Diagnostic Technicians
DESCRIPTION:Scientific and Technical Sessions for Senior Clinical and Biomedical Diagnostic Technicians \n  \nObjective: \nTo update knowledge on diagnostic procedures\, quality control\, and new laboratory tools. \n  \nSpecific objectives: \nTo analyze the quality control procedures applied to hematopoietic progenitor cells in the context of allogeneic transplantation. \nTo determine the diagnostic utility and clinical application of the GFAP and UCH-L1 biomarkers in patients with mild acute brain injury. \nTo evaluate the utility of automated hematology systems and their correlation with conventional morphological methods. \n  \nDate: \nStart Date: September 21\, 2026 \nEnd: December 30\, 2026 \n  \nLocation: \nCAUSA DP0518 Auditorium \nProgram: \n\n\n\nDate / Time\nLocation\nSpeaker\nContent\n\n\nSeptember 21\, 26\nCAUSA DP0518 AUDITORIUM\n– María Magdalena Barbero García\n– CORRELATION BETWEEN HEMOGLOBIN LEVELS MEASURED BY THE GEM 5000 WERFEN BLOOD GAS ANALYZER AND THE SIEMENS ADVIA 2120I CYTOMETER\n\n\n13:30 / 15:30\n\n\n10/26/19\nCAUSA DP0518 AUDITORIUM\n– REBECA ORTEGA HERRERA\n– QUALITY CONTROL OF HEMATOPOIETIC PROGENITOR CELLS USING CLONOGENIC ASSAYS IN THE CONTEXT OF ALLOGENEIC TRANSPLANTATION. \nFUNCTIONAL COMPARISON OF FRESH VERSUS CRYOPRESERVED PROGENITOR CELLS\n\n\n13:30 / 15:30\n\n\n11/23/26\nCAUSA DP0518 AUDITORIUM\n– SOFIA GONZALEZ MARTIN\n– DETERMINATION OF BIOMARKERS FOR MILD ACUTE BRAIN INJURY IN THE EMERGENCY ROOM LABORATORY: GFAP AND UCH-L1\n\n\n13:30 / 15:30\n\n\n12/14/26\nCAUSA DP0518 AUDITORIUM\n– MARIA DE LOS ANGELES GOMEZ GONZALEZ\n– CORRELATION BETWEEN THE ADVIA 2120 AUTOMATED LEUKOCYTE DIFFERENTIAL COUNT AND THE MORPHOLOGICAL COUNT ASSISTED BY CELIAVISION\n\n\n13:30 / 15:30\n\n\n\nEnrollment:   \nREGISTRATION: \nIndividually\, through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \nSeats: \n30 for IBSAL staff \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n 
URL:https://ibsal.es/en/evento/scientific-and-technical-sessions-for-senior-clinical-and-biomedical-diagnostic-technicians/
LOCATION:Hospital Clínico. Complejo Asistencial Universitario de Salamanca (Salamanca University Welfare Complex)\, Pº de San Vicente\, 182\, Salamanca\, Salamanca\, Spain
CATEGORIES:Sacyl Course
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260921
DTEND;VALUE=DATE:20261231
DTSTAMP:20261005T104413Z
CREATED:20261005T104413Z
LAST-MODIFIED:20261005T104413Z
UID:10002432-1789948800-1798675199@ibsal.es
SUMMARY:Scientific and Technical Sessions for Senior Clinical and Biomedical Diagnostic Technicians
DESCRIPTION:  \nScientific and Technical Sessions for Senior Clinical and Biomedical Diagnostic Technicians \n  \nObjective: \nTo update knowledge on diagnostic procedures\, quality control\, and new laboratory tools. \n  \nSpecific objectives: \nTo analyze the quality control procedures applied to hematopoietic progenitor cells in the context of allogeneic transplantation. \nTo determine the diagnostic utility and clinical application of the GFAP and UCH&8209;L1 biomarkers in patients with mild acute brain injury. \nTo evaluate the utility of automated hematology systems and their correlation with conventional morphological methods. \n  \nDate: \nStart Date: September 21\, 2026 \nEnd: December 30\, 2026 \n  \nLocation: \nCAUSA DP0518 Auditorium \nProgram: \n\n\n\nDate / Time\nLocation\nSpeaker\nContent\n\n\nSeptember 21\, 26\nCAUSA DP0518 AUDITORIUM\n– María Magdalena Barbero García\n– CORRELATION BETWEEN HEMOGLOBIN LEVELS MEASURED BY THE GEM 5000 WERFEN BLOOD GAS ANALYZER AND THE SIEMENS ADVIA 2120I CYTOMETER\n\n\n13:30 / 15:30\n\n\n10/26/19\nCAUSA DP0518 AUDITORIUM\n– REBECA ORTEGA HERRERA\n– QUALITY CONTROL OF HEMATOPOIETIC PROGENITOR CELLS USING CLONOGENIC ASSAYS IN THE CONTEXT OF ALLOGENEIC TRANSPLANTATION. \nFUNCTIONAL COMPARISON OF FRESH VERSUS CRYOPRESERVED PROGENITOR CELLS\n\n\n13:30 / 15:30\n\n\n11/23/26\nCAUSA DP0518 AUDITORIUM\n– SOFIA GONZALEZ MARTIN\n– DETERMINATION OF BIOMARKERS FOR MILD ACUTE BRAIN INJURY IN THE EMERGENCY ROOM LABORATORY: GFAP AND UCH-L1\n\n\n13:30 / 15:30\n\n\n12/14/26\nCAUSA DP0518 AUDITORIUM\n– MARIA DE LOS ANGELES GOMEZ GONZALEZ\n– CORRELATION BETWEEN THE ADVIA 2120 AUTOMATED LEUKOCYTE DIFFERENTIAL COUNT AND THE MORPHOLOGICAL COUNT ASSISTED BY CELIAVISION\n\n\n13:30 / 15:30\n\n\n\nEnrollment:   \nREGISTRATION: \nIndividually\, through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \nSeats: \n30 for IBSAL staff \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n 
URL:https://ibsal.es/en/evento/scientific-and-technical-sessions-for-senior-clinical-and-biomedical-diagnostic-technicians-3/
CATEGORIES:Sacyl Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260924T081500
DTEND;TZID=UTC:20261210T094500
DTSTAMP:20260901T110351Z
CREATED:20260831T120427Z
LAST-MODIFIED:20260901T110351Z
UID:10002361-1790237700-1796895900@ibsal.es
SUMMARY:2nd Edition of the Continuing Education Program on Inflammatory Nasal and Sinus Diseases in Castile and León
DESCRIPTION:“Second Edition of the Continuing Education Program on Inflammatory Nasal and Sinus Diseases in Castile and León” \n  \nObjective: \n\n\n\nTo determine therapeutic management and experience in treating patients with severe chronic non-polypoid sinusitis (CNPS). \nTo establish criteria for the indication and treatment of various nasosinusal conditions (epistaxis\, septopyramidal deviation\, eosinophilic otitis).\n\n\n\n  \nSpecific objectives: \n  \n\n\n\n-Establish a treatment strategy\, incorporating biologics into the current treatment algorithm. \n-Evaluation of real-world outcomes of treatment with biologic drugs. \n-Establish a standardized approach to the management of epistaxis in the emergency department. \n-Establish the criteria for surgical indication and the surgical techniques for patients with septopyramidal deviation.\n\n\n\n  \nLocation: \nTEAMS link. \n  \nProgram: \n\n\n\nCourse Date\nSchedule\nContent\nSPEAKER \n\n\n  Thursday\, September 24\, 2026\n8.15-9.45\n  \n‘s Septorhinoplasty Online \n \nMs. María Gil Melcón \nHead of the Otolaryngology Section. CAUSA \n\n\n  Thursday\, November 5\, 26\n8.15-9.45\n  \nEosinophilic Otitis: Diagnosis\, Treatment\, and Outcomes in CAUSA \nOnline \n \nMs. Susana Marcos Alonso   \nL.E.A. Otolaryngology. CAUSE \n\n\n  Thursday\, December 10\, 2026\n8.15-9.45\nDupilumab in Real-World Practice in CAUSA \nOnline.\nMr. Juan Carlos del Pozo de Dios   \nL.E.A. Otolaryngology. CAUSE. \n\n\n\n  \nEnrollment:   \nREGISTRATION: \nThe registration deadline is Tuesday\, September 22\, 2026; you must register individually through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \n  \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n 
URL:https://ibsal.es/en/evento/2nd-edition-of-the-continuing-education-program-on-inflammatory-nasal-and-sinus-diseases_castile-and-leon/
CATEGORIES:Course
ATTACH;FMTTYPE=image/png:https://ibsal.es/wp-content/uploads/2026/08/Regeneron-logo--scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20261001T081500
DTEND;TZID=UTC:20261127T094500
DTSTAMP:20260902T075759Z
CREATED:20260901T105743Z
LAST-MODIFIED:20260902T075759Z
UID:10002363-1790842500-1795772700@ibsal.es
SUMMARY:2nd Edition of the Continuing Education Program on Inflammatory Nasal and Sinus Pathology in Salamanca
DESCRIPTION:“2nd Edition of the Continuing Education Program on Inflammatory Nasal and Sinus Diseases in Salamanca” \n  \nObjective: \n\n\n\nTo determine therapeutic management and experience in treating patients with severe chronic non-polypoid sinusitis (CNPS). \nTo establish criteria for the indication and treatment of various nasosinusal conditions (epistaxis\, septopyramidal deviation\, eosinophilic otitis). \n \n\n\n\n  \nSpecific objectives: \n  \n\n\n\n-Establish a treatment strategy\, incorporating biologics into the current treatment algorithm. \n-Evaluation of real-world outcomes of treatment with biologic drugs. \n-Establish a standardized approach to the management of epistaxis in the emergency department. \n-Establish the criteria for surgical indication and the surgical techniques for patients with septopyramidal deviation. \n \n\n\n\n  \nDate: October 1\, 2026\, through November 26\, 2026 \n  \nLocation: \nLibrary of the Otolaryngology Department at the University Hospital of Salamanca. \n  \nProgram: \n\n\n\nCourse Date\nSchedule\nContent\nSpeaker\n\n\nThursday\, \n\, October 1\, 26\n8.15-9.45\nMultiple-choice case studies of patients with cPN-CSC treated with biologic drugs. \nIn-person\nMs. Susana Marcos Alonso \nL.E.A. Otolaryngology. CAUSE \n\n\nThursday\, \n\, October 22\, 2026\n8.15-9.45\nEpistaxis: Therapeutic Management. \nIn-person\nMs. María Gil Mencón  \nHead of the Otolaryngology Section. CAUSA \n\n\nThursday\, November 26\, \n\n8.15-9.45\nComprehensive Treatment of cPN-CSR: Surgery and Biologics. \nIn-Person\nMr. Fernando Franco Calvo \nHead of the Otolaryngology Department. CAUSA \n\n\n\nEnrollment:   \nREGISTRATION: \nThe registration deadline is Friday\, September 29\, 2026; please register individually through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \n  \n  \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n 
URL:https://ibsal.es/en/evento/2nd-edition-of-the-continuing-education-program-on-inflammatory-nasal-and-sinus-diseases-salamanca/
CATEGORIES:Course
ATTACH;FMTTYPE=image/png:https://ibsal.es/wp-content/uploads/2026/08/Regeneron-logo--scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261014
DTEND;VALUE=DATE:20261125
DTSTAMP:20261016T071608Z
CREATED:20261016T070420Z
LAST-MODIFIED:20261016T071608Z
UID:10002451-1791936000-1795564799@ibsal.es
SUMMARY:III Research Grant: MALENA GARRIDO - Spanish Scleroderma Association (A.E.E.)
DESCRIPTION:Purpose\nThe purpose of this call for proposals is for the Spanish Scleroderma Association (A.E.E.) to award grants to high-quality research projects on scleroderma conducted under the supervision of a principal investigator (PI). \nThe research project must have a clear impact on the quality of life of patients with scleroderma\, and there must be a solid research foundation to support the hypothesis presented in the proposal. \nThe projects submitted must be carried out entirely in Spain. \n  \nRequirements\nAny IP applying for this call must: \n— Be affiliated with a public or private nonprofit organization in Spain that is qualified to conduct scientific research. \n— Have at least two research articles published or accepted for publication as an author or co-author in a peer-reviewed scientific journal at the time of application. Publications dated after the application deadline will not be accepted.  \n  \nFeatures of the Grant\nThis grant amounts to 22\,000 euros gross and will be disbursed in two payments: 50% of the total amount upon award\, and the remaining 50% upon submission of a preliminary report on the work completed to date.  \n— The award of this grant shall not preclude the recipient from receiving other public or private funding for the evaluated project. However\, the existence of another source of funding will result in a penalty under the scoring criteria.  \n— Members of the Board of Directors or the Scientific Committee of the Spanish Scleroderma Association may not participate in this grant program as applicants or collaborators. \n— The researcher must notify the A.E.E. of any cause of incompatibility. \n  \nApplication Requirements and Content\n— Applicants may submit only one proposal for this call for proposals. If the same project is submitted by different researchers\, both applications will be rejected.  \n— If the applicant is not selected\, he or she may resubmit an application in future calls for proposals\, provided that changes have been made to the submitted project or to the laboratory where the project will be carried out\, in accordance with the comments in the evaluation report. \nSubmitting incomplete documentation may result in the denial of the application. Each application must include the following documents:  \nPHASE I. PRELIMINARY PROPOSAL\n— Scanned copy of both sides of the national ID card\, valid residence permit\, or passport.\n— Candidate’s Abbreviated Curriculum Vitae (CVA) (maximum 4 pages). Achievements and contributions must be clearly reflected\, particularly in publications (indicate position on the list of authors)\, research projects\, and patents.\n— Preliminary proposal (PDF format\, maximum 4 pages) including: background\, research hypothesis\, social impact (relevance of the proposal)\, and bibliography. \nPHASE II: COMPLETE PROPOSAL\nThe ideas preselected during the first evaluation phase will be notified and must submit a complete proposal that includes: \n— Scientific research report: statement of responsibility\, scientific abstract\, popular science summary of the project\, plan for disseminating scientific results to the public\, and collaboration with the A.E.E.\, background\, objectives\, methodology\, work plan\, timeline\, significance of the work and its scientific and social impact\, justification of the proposal’s innovative nature\, ethical implications\, references and scientific background\, structure of the recipient group\, and a reasoned justification of the various items for which the requested grant will be used. \nThe affidavit signed by the applicant\, included in the scientific report\, must indicate whether any other type of grant or prior funding from public or private sources has been obtained or requested in connection with the submitted proposal. If such information is clearly omitted during the selection\, award\, or monitoring process for the grant\, the A.E.E. reserves the right to reject the application or\, as the case may be\, revoke the grant award and request the return of any funds disbursed.  \n— Budget: Justifying the various items for which the requested grant will be used. Expenses related to patents and intellectual property must be included in the budget.\n— Approval from the research center where the project will be carried out\, which includes: \n\nA reasoned report from the investigative committee or the school administration.\nLetter of acceptance from the center’s management. This letter must be signed by the center’s legal representative. All industrial and intellectual property rights that may arise from the funded “\n” projects will be distributed in accordance with the rules and agreements of the RESEARCH CENTER.  \nSpecification of the percentage that the research center will apply to the project for administrative expenses.\n\n  \nSubmission and Deadlines\n— Applicants must submit all documentation in a single email to the following address: beca_mg@esclerodermia.com. \n— The subject line of the email must include the word “SCHOLARSHIP” followed by the IP’s two last names. \n— The deadline for submitting applications is November 30\, 2026\, at 12:00 a.m. (peninsular time). Applications submitted after this deadline will not be accepted.  \n— The applicant is responsible for all the information contained in the submitted documentation and guarantees its accuracy. If the application is submitted correctly\, the user will receive a confirmation receipt.  \n— If the submitted application is incomplete or does not meet the requirements of this call for applications\, it will be rejected\, and there will be no opportunity to correct any errors. \n  \nCOMPLETE RULES \n 
URL:https://ibsal.es/en/evento/iii-research-grant-malena-garrido-spanish-scleroderma-association-a-e-e/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261021
DTEND;VALUE=DATE:20270130
DTSTAMP:20261026T092118Z
CREATED:20261026T090010Z
LAST-MODIFIED:20261026T092118Z
UID:10002453-1792540800-1801267199@ibsal.es
SUMMARY:International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Award
DESCRIPTION:Features\nFunding from the International Myeloma Society (IMS) and the Paula and Rodger Riney Foundation supports translational research projects on multiple myeloma and other plasma cell disorders. Their goal is to advance findings that can be translated into clinical practice\, thereby improving the prevention\, early detection\, diagnosis\, and treatment of these diseases.  It is essential that the project have a clear translational focus and a result that is potentially applicable in clinical practice; basic research on myeloma alone is not sufficient. \nTranslational research projects are accepted in all areas of plasma cell disorders\, particularly multiple myeloma. The research areas considered include:  \n\n\n\n\nDevelopment of biomarkers and methods for diagnosis or early detection. \n\n\n\n\n\n\nNew molecular and imaging techniques. \n\n\n\n\n\n\nDevelopment and evaluation of drugs or biological agents. \n\n\n\n\n\n\nIdentification of new therapeutic targets using human biological samples\, including those from clinical trials. \n\n\n\n\n\n\nPreclinical or clinical research with the potential to change the way myeloma is prevented\, diagnosed\, or treated. \n\n\n\n\nThe project must have an initial duration of 12 months\, although an extension for an additional year may be requested on an exceptional basis. Funding covers personnel expenses\, laboratory supplies\, services\, and travel. Inventory items are not permitted unless their necessity is specifically justified.   Funding ranging from 175\,000 USD to 250\,000 USD per project. \nRequirements:\n\n\n\n\nPrincipal Investigator (PI) Profile: The PI must be a university professor (faculty member) or an established researcher with an MD and/or PhD. \n\n\n\n\n\n\nResearch experience: We are seeking a researcher with a proven track record. Researchers from other fields who wish to focus their research on myeloma are also encouraged to apply.  \n\n\n\n\n\n\nIMS Membership: The principal investigator or one of the co-investigators must be a member of the International Myeloma Society. \n\n\n\n\n\n\nAcknowledgment Requirement: Publications and presentations resulting from this grant must acknowledge the IMS and the Paula and Rodger Riney Foundation as sources of funding. \n\n\n\n\n\n\nTranslational impact: The proposal must explain how its results can be translated into clinical practice. \n\n\n\n\nWomen and researchers from underrepresented groups are especially encouraged to submit applications \nHow to apply\nThe application must be completed in English. The following documentation is required:  \n\nOfficial application form. It must be completed and approved by the institution. \nScientific report\, bibliographic references\, scientific CV (biosketch)\, budget\, and statement of eligibility and translation.\n\nApplications are submitted through the IMS Grant Management System \nThe call for applications for 2027 is now open\, and the deadline is January 29\, 2027\, at 11:59 p.m. (EST) (the deadline corresponds to 5:59 a.m. on January 30\, 2027\, Spanish peninsular time).
URL:https://ibsal.es/en/evento/international-myeloma-society-ims-and-paula-and-rodger-riney-foundation-translational-research-award/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261021
DTEND;VALUE=DATE:20270130
DTSTAMP:20261026T103746Z
CREATED:20261026T101932Z
LAST-MODIFIED:20261026T103746Z
UID:10002457-1792540800-1801267199@ibsal.es
SUMMARY:International Myeloma Society (IMS) Career Development Award 2027
DESCRIPTION:Features\nThe International Myeloma Society (IMS) Career Development Award 2027 aims to advance the academic careers of young researchers working in the field of plasma cell disorders by fostering collaboration among institutions and providing training in a research environment different from that of their home institution. \nFunding is provided for one-year fellowships of up to 75\,000 USD. The recipient receives a free one-year IMS membership. The host institution must be different from the home institution and provide a substantial change in the research environment.   \nRequirements\nThe researcher must be working in the field of multiple myeloma and must also meet the requirements related to professional experience and mobility. \n\n\n\n\nDegree: MD (Medicine) or PhD (Doctorate). Candidates currently pursuing a doctoral degree focused on plasma cell disorders will also be considered.  \n\n\n\n\n\n\nCareer stage: You should not yet be an independent researcher. \n\n\n\n\n\n\nFuture career path: You must intend to pursue a career in the field of plasma cell disorders. \n\n\n\n\n\n\nPrevious funding: Applicants must not have received funding from the U.S. NIH or its international equivalent. \n\n\n\n\n\n\nEmployment Relationship with the Host Institution: You cannot already have an employment contract with the laboratory that will host you. \n\n\n\n\n\n\nChange of institution: The research must be conducted at an institution other than the researcher’s home institution and involve a substantial change in the research environment. Changes between laboratories within the same institution or between laboratories located in the same metropolitan area are not permitted.  \n\n\n\n\n\n\nIMS Membership: The principal investigator at the home institution or the host institution must be an IMS member. \n\n\n\n\n\n\nLimit per laboratory: Each host laboratory may submit a maximum of one application per cycle. \n\n\n\n\nWe especially encourage nominations of women and members of underrepresented minorities. \nHow to apply\nThe application must be completed in English. The following documentation is required:  \n\nOfficial application form. It must be completed and approved by the institution. \nResearch proposal\, bibliographic references\, the candidate’s resume\, letters of support from the home institution and the host laboratory\, and a budget and justification.\n\nApplications are submitted through the IMS Grant Management System \nThe call for applications for 2027 is now open\, and the deadline is January 29\, 2027\, at 11:59 p.m. (EST) (the deadline corresponds to 5:59 a.m. on January 30\, 2027\, Spanish peninsular time).
URL:https://ibsal.es/en/evento/international-myeloma-society-ims-career-development-award-2027/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Helsinki:20261103T000000
DTEND;TZID=Europe/Helsinki:20261124T140000
DTSTAMP:20261008T171526Z
CREATED:20261008T171345Z
LAST-MODIFIED:20261008T171526Z
UID:10002439-1793664000-1795528800@ibsal.es
SUMMARY:Knowledge Generation Projects and Initiatives for the Training of Pre-doctoral Research Personnel 2026
DESCRIPTION:Purpose\nThe purpose of this call for proposals is to fund research projects aimed at both fostering the generation and significant advancement of scientific knowledge and high-quality research\, and at finding solutions to societal challenges\, by promoting initiatives at both the national and bilateral international levels. \nIn addition\, funding may be provided for activities aimed at training pre-doctoral researchers through the completion of a doctoral dissertation related to the aforementioned research projects. \n  \nBeneficiaries\nUniversities\, public R&D&I centers\, technology centers\, and public and private nonprofit organizations involved in science\, technology\, research\, and innovation. \n  \nProject Characteristics\nThere are two types of projects: \n1) Research Non-Targeted: projects without a predefined thematic focus whose primary objective is the advancement of knowledge\, regardless of the time frame or scope of application. \n2) Research Focused: aimed at solving specific problems linked to the thematic priorities associated with society’s major challenges\, as outlined in Annex III of the call for proposals. \nProjects may be carried out individually\, with one or two principal investigators and a research team\, or in a coordinated\, with several subprojects\, each with one or two principal investigators and a research team. \nWithin each category\, there are two types of projects based on the profile of the lead partner: \n\na) Projects Type A: Principal Investigators with significant and innovative scientific and technical contributions and leadership capabilities.\nb) Projects Type B: Principal Investigators with a proven track record in research.\n\nType B includes the following types of projects\, depending on the modality: \nResearch Methodology  Unoriented \n— Type I: Projects carried out within the framework of an international bilateral collaboration involving at least two different multinational research teams\, one consisting of one or more Spanish institutions and the other consisting of one or more foreign research institutions.\nThese applications may be submitted for all thematic areas listed in Annex II. \n– Applied Research Track \n— RTA Type\, exclusively in the form of Targeted Research projects\, proposed by the CSIC’s National Institute for Agricultural and Food Research and Technology (INIA) and the public agricultural or food R&D&I centers under the jurisdiction of the Autonomous Communities\, which are part of the INIA (CSIC)-CCAA \nThe duration of the projects and subprojects will generally be 3 or 4 years\, depending on what is justified by the nature of the activities described in the scientific and technical report. \n  \nCharacteristics of Programs for Pre-Doctoral Research Training\nGrants for the training of pre-doctoral research staff are intended to fund activities aimed at training new Ph.D. graduates through the completion of a doctoral dissertation associated with a research project funded under this call for proposals\, including funding for the costs of hiring pre-doctoral research staff\, stays at R&D centers\, and tuition fees associated with doctoral programs. Additionally\, within the framework of these grants\, funding may be provided for a postdoctoral orientation period (POP)\, once the doctoral degree has been obtained\, aimed at the professional development and specialization of these researchers\, provided that the degree is obtained during the implementation period of the initiative for the training of pre-doctoral researchers.  \nThe actions will have a maximum duration of four years. \nThe process of evaluation and selection of the person to be hired shall be the responsibility of the beneficiary entity. The beneficiary organization must prepare a report describing the selection process and justifying the suitability of the selected candidate\, based on the criteria established in the call for applications.  \n  \nKnowledge Generation Projects\nThe objectives are to contribute to the development of the national and international leadership capacity of research teams in public and private nonprofit entities involved in R&D&I\, by facilitating their mobility and promoting their participation and success in European and international programs and projects; to enable the adoption of an interdisciplinary and multidisciplinary approach involving research groups with a critical mass capable of generating synergies among different scientific and technical approaches and promoting significant advances in scientific knowledge. \nThe grants provided for in this call for proposals will be used to cover costs directly and unambiguously related to the development and implementation of the activities for which they have been awarded. Funding may be applied to direct and indirect costs\, with indirect costs set at a fixed percentage of 25% of the project’s direct expenses.  \nThe grants may cover up to 100 percent of the marginal costs for which funding is requested. \n  \nActivities for the training of pre-doctoral research staff associated with the projects:\nThe goal is to train new generations of researchers who will acquire the necessary skills while working in top-tier research teams\, including the promotion of mobility through short-term stays at other national and international centers\, as well as scientific and technological infrastructures and facilities. \nThe grants will cover the following expenses: hiring costs\, severance pay upon contract termination\, and expenses related to placements at R&D centers and enrollment in doctoral programs. They may include a postdoctoral orientation period (POP) of up to 12 months\, to be completed after obtaining a doctoral degree within the project’s implementation period\, aimed at professional development and specialization.  \n  \nApplication Deadline\nThere will be a single application period\, from November 3 to November 24\, 2026\, at 2:00 p.m. (Spanish peninsular time). \n  \nMore information: https://www.aei.gob.es/convocatorias/buscador-convocatorias/proyectos-generacion-conocimiento-actuaciones-formacion-7
URL:https://ibsal.es/en/evento/knowledge-generation-projects-and-initiatives-for-the-training-of-pre-doctoral-research-personnel-2026/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261104
DTEND;VALUE=DATE:20270121
DTSTAMP:20261111T141216Z
CREATED:20261111T135228Z
LAST-MODIFIED:20261111T141216Z
UID:10002475-1793750400-1800489599@ibsal.es
SUMMARY:PARTNERSHIP European Partnership for Personalized Medicine (EP PerMed)
DESCRIPTION:Characteristics\n The EP PerMed JTC 2027 call for proposals\, CGT4PM2027 “Cell and Gene Therapy for Personalized Medicine” \, has been published. It is a fairly specific call: the focus must be on the development and validation of a personalized cell and/or gene therapy. \nThe goal is to fund multinational innovative research projects in personalized medicine (PM) that develop and validate new cell and/or gene therapies. The aim is to combine academic\, clinical\, and private-sector research. The proposal must focus on the development and validation of an innovative and novel cell or gene therapy for personalized medicine. \nIt must incorporate at least one of these approaches: \n\nSomatic cell therapies\, such as stem cells\, organoids\, or immune system cells.\nGene therapies\, involving the replacement\, addition\, or deletion of genes\, using viral or non-viral vectors or genome editing.\nCombined cell-gene therapies\, such as genetically modified cells.\nNew biological products such as mRNA\, other nucleic acids\, or extracellular vesicles used as vehicles for gene-based therapeutic procedures.\n\n  \nIn addition\, the project must: \n\nuse physiologically relevant preclinical models: human cell cultures\, organoids\, organs-on-a-chip\, animal models\, etc.;\nhave solid preliminary data;\npresent a credible path to clinical application;\ninclude a specific work package for preclinical development and early CMC\, tailored to the product’s maturity;\nconsider\, where applicable\, aspects of scalable manufacturing\, a control strategy\, and a path toward GMP-compliant manufacturing.\n\nAdditionally\, the Carlos III Health Institute (ISCIII) is participating in this call as the national funding agency. \nRequirements\nThe consortium must meet\, at a minimum: \n\n3 funded partners from 3 different countries.\nThe countries must be EU Member States or countries associated with Horizon Europe whose funding agencies are participating in the call.\nAll three partners must be independent legal entities.\nEach partner must be eligible and apply for funding from its national/regional funding agency.\nThe coordinator must be eligible to receive funding from their national/regional funding agency.\nThe coordinator cannot be changed between the pre-proposal and the full proposal.\nIt is mandatory to include at least one Early-Career Researcher (ECR) as a principal investigator.\nA maximum of 2 partners per funding agency.\nA maximum of one self-funded partner in a consortium that has at least three funded partners.\n\nSubmission deadline.\nThe following table lists the various dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 4\, 2026\n\n\nDeadline for Pre-Proposals\nJanuary 20\, 2027\, (2:00 p.m. CET)\n\n\nNotification of the results of the pre-proposal\nApril 2027\n\n\nDeadline for full proposals\nMay 25\, 2027\, (2:00 p.m. CET)\n\n\nRebuttal stage\nAugust 2027\n\n\nNotification of Funding Decisions\nOctober 2027\n\n\n\n  \n 
URL:https://ibsal.es/en/evento/partnership-european-partnership-for-personalized-medicine-ep-permed-2/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261211
DTSTAMP:20261116T095436Z
CREATED:20261116T090137Z
LAST-MODIFIED:20261116T095436Z
UID:10002491-1794441600-1796947199@ibsal.es
SUMMARY:AECC 2027 Call for Strategic Projects
DESCRIPTION:Purpose and Objective\nThe purpose of this call for proposals issued by the Scientific Foundation of the Spanish Association Against Cancer (hereinafter\, the Foundation) is to award grants for high-quality cancer research projects aligned with the strategic areas defined by the Spanish Association Against Cancer (hereinafter\, the Association): palliative care\, epidemiology\, radiation oncology\, and surgical oncology. \nProjects must be carried out under the supervision of a group leader\, take place entirely in Spain\, and demonstrate clear strategic importance to the Association\, as well as a significant impact on cancer patients. \nThis call for proposals is intended for research projects led by a group leader. In exceptional cases\, and provided there is adequate justification\, the participation of another group leader with an associated budget will be accepted. \nFor collaborative projects\, we recommend reviewing the call for proposals for General Project Grants; Collaborative category. \nAll aspects of the call for proposals will be managed through the Foundation’s grant management platform (Grant Management System) \n  \nRequirements\n Requirements for the Applicant (Group Leader) \n\nHold a doctoral degree.\nBe contractually affiliated with a public or private nonprofit organization in Spain capable of conducting scientific research. The project must be carried out at that organization\, which must be listed in the application.\nPublications:\nTwo research articles as first author or corresponding author\, published or accepted in peer-reviewed international journals in the first quartile (according to JCR or SJR indices) at the time of application. Publications dated after the application deadline will not be accepted.\nOnly original articles will be considered; reviews\, book chapters\, and patents are excluded.\n\n  \nProposal Requirements \n\nThe research project must have a clear translational component\, grounded in a solid foundation of basic research that supports the hypothesis presented in the proposal.\nThe project must fall within the strategic areas defined by the Association: palliative care\, epidemiology\, radiation oncology\, and surgical oncology.\nA description must be provided of why this project is strategic for the Association and for cancer patients.\n\nResearch center \n\nFor the purposes of this call for proposals\, a research center (hereinafter\, “Center”) is defined as any public or private nonprofit entity capable of conducting scientific research in Spain. Projects carried out in industrial research laboratories will not be accepted. Applications from research centers that receive donations from private companies will be accepted.\n\nGrant Details\nDuration \nThe \ngrant\n will have a duration of 3 years from the start date indicated in the specific annex to the framework agreement governing the specific conditions of the grant awarded. \nFinancial Assistance \nThis grant has a maximum budget of 150\,000 euros (gross) over 3 years\, at a rate of up to 50\,000 euros (gross) per year for the implementation of the project. The eligible expense categories are detailed in the Annex: Guide to Eligibility and Justification of Expenses\, available in the “Documentation” section of the call for proposals. \n  \nSubmission of Applications\nApplicants may submit only one proposal for this call for proposals. \nIf the same project is submitted by different applicants\, both applications will be rejected. If the applicant is not awarded the grant\, they may reapply in future calls for proposals\, provided that relevant changes have been made to the submitted project or to the laboratory where the project will be carried out\, in accordance with the observations in the evaluation report. \nTo this end\, the Foundation will retain the scientific records of the projects submitted for a period of 5 years to verify that new applications include substantial modifications. All projects must comply with current legal regulations and applicable ethical principles. \nThe use of artificial intelligence (AI) tools is permitted to assist with writing\, translation\, language refinement\, code generation or review\, structuring ideas\, and other tasks related to the preparation of the application. The applicant is responsible at all times for the final content submitted and must ensure its accuracy\, completeness\, and compliance with the call for proposals. Whenever possible\, it is recommended to disclose the use of such tools. \n  \nContent of the Applications \n  \nApplication Deadline\nThe  \napplication period\n begins on November 12\, 2026\, and ends on December 10\, 2026\, at 3:00 p.m. (Peninsular time). \nThe system will not accept submissions after the application deadline\, and only those applications submitted within the application period will be evaluated. \nIt is recommended that applications be submitted well in advance to avoid any issues with the GMS platform. Once completed\, the applicant will review and confirm all the information before submitting it. \nThe applicant is responsible for all information contained in the submitted documentation and guarantees its accuracy. If the application is submitted correctly\, the user will receive a confirmation notice at the email address noreply@smartsimple.ie \n  \nComplete guidelines for the call for applications\nhttps://www.contraelcancer.es/sites/default/files/ayudas/2026-11/Bases_Proyectos_PROYECTOS%20ESTRAT%C3%89GICOS%20AECC_2027.pdf \n 
URL:https://ibsal.es/en/evento/aecc-2027-call-for-strategic-projects/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Helsinki:20261112T000000
DTEND;TZID=Europe/Helsinki:20261126T140000
DTSTAMP:20261008T164756Z
CREATED:20261008T164721Z
LAST-MODIFIED:20261008T164756Z
UID:10002437-1794441600-1795701600@ibsal.es
SUMMARY:Juan de la Cierva Grants 2026
DESCRIPTION:Call for Proposals Summary\nThe State Research Agency is offering 500 grants to encourage young people who hold a Ph.D. to complete their postdoctoral research training at Spanish R&D centers. \nThe total budget for this call for proposals is €61\,050\,000\, of which the following amounts will be allocated for each grant: \n\n35\,700€/year to co-finance the salaries and employer Social Security contributions for the hired individuals (the minimum compensation to be received by the hired individuals will be 31\,200€ per year).\n€15\,000 to cover the JDC researcher’s expenses\, preferably for national and international mobility activities. It may also be used for other activities directly related to the conduct of the researcher’s research. \n\n  \nRequirements\nRequirements for applicants: \n\n\nThe following entities with their own legal personality may apply for and receive the grants\, provided they are validly incorporated and have tax residency or a permanent establishment in Spain\, and are authorized to hire employees: \n\nPublic Research Organizations.\nPublic universities\, their university institutes\, and private universities with proven capacity and experience in R&D&I.\nPublic and private nonprofit healthcare organizations and institutions that are affiliated with or have agreements with the National Health System and that conduct R&D&I activities.\nAccredited health research institutes.\nState-level Technology Centers and State-level Technology Innovation Support Centers.\nOther public R&D&I centers\, with their own legal personality\, whose articles of incorporation\, governing regulations\, or corporate purpose specify R&D&I as their primary activity.\nPrivate\, nonprofit R&D&I centers with their own legal personality that define R&D&I as their primary activity in their bylaws\, in the regulations governing them\, or in their corporate purpose.\nPublic agricultural and food research centers of the Autonomous Communities\, which are part of the INIA (CSIC)-CCAA system.\n\n  \nApplications must be submitted by the R&D center to which the participating individual’s supervising researcher is affiliated\, and the following requirements must be met: \n\nA single person may be listed as a participant in only one R&D Center application.\nA supervising researcher may only be listed as such on a single application. A supervisor is defined as the person who will be directly responsible for supervising and guiding the participant’s professional development. \nA person who has served as a mentor in an application submitted for the 2025 call for Juan de la Cierva grants and who has been disqualified due to falsification or similar circumstances in the documentation regarding the mentor—submitted for the evaluation process—may not serve as a mentor.\n\n\nCandidate requirements:\n\nParticipants must meet the following requirements: \n\nHold a doctoral degree obtained on a date between January 1\, 2024\, and December 31\, 2026. The earlier deadline of January 1\, 2024\, may be extended if\, between the date the doctoral degree was awarded and the deadline for completing the application form\, any of the situations indicated in the call for applications (temporary disability\, leave for pregnancy\, childbirth\, adoption\, etc.) and that have affected research activity. For applicants participating in the category for people with disabilities\, the date of obtaining the doctoral degree must fall between January 1\, 2023\, and December 31\, 2026; extensions may also be granted for justified periods of inactivity.  \nApply to join an R&D center other than the one where you completed your pre-doctoral training.\nNot having submitted an application for the Ramón y Cajal grants\, for the 2026 call for applications\, by the deadline for submitting applications for these grants.\nNot having been a recipient of funding from previous calls for proposals under the Juan de la Cierva\, Postdoctoral Training\, Juan de la Cierva-Training\, or Juan de la Cierva-Incorporation programs. A “recipient” of these programs is defined as any person named in any of the award decisions from previous calls for proposals for these programs\, regardless of whether or not they ultimately joined the R&D Center. \nIf you were an applicant for the 2025 Juan de la Cierva grant program:\n\nThe application must have received a score of 50 points or higher.\nThe application must not have been rejected on the grounds of false information or similar circumstances in the documentation regarding the participant that was submitted for the evaluation process.\n\n\n\n\n\n  \nCompatibility\nIndividuals hired under these grants may provide supplementary assistance with teaching duties\, either at their own institution or at other institutions\, for a maximum of 100 hours per year\, at their own request and with the approval of their institution\, while complying\, where applicable\, with current regulations regarding conflicts of interest for personnel employed by public administrations. \n  \nApplications\nThe deadline for participants to complete and sign the electronic application form will be from November 12\, 2026\, to   November 26\, 2026\, at 2:00 p.m. \nSubsequently\, applications for participation will be submitted by the R&D centers through the online application\, which will be available starting November 12\, 2026\, through December 3\, 2026\, at 2:00 p.m.   \nApplications for participation are submitted by R&D centers\, which include the names of the participants to be added to the research teams. \n  \nApplications for participation must be submitted by R&D centers through the electronic channels provided for this purpose on the State Secretariat for R&D&I’s Electronic Portal. \n  \nMore information\nLink to the call for applications:  https://www.aei.gob.es/convocatorias/buscador-convocatorias/ayudas-contratos-juan-cierva-2026 \n  \n 
URL:https://ibsal.es/en/evento/juan-de-la-cierva-grants-2025-2/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261211
DTSTAMP:20261116T082459Z
CREATED:20261116T080749Z
LAST-MODIFIED:20261116T082459Z
UID:10002489-1794441600-1796947199@ibsal.es
SUMMARY:AECC 2027 Call for General Projects
DESCRIPTION:Purpose and Objective\nThe purpose of this call for proposals by the Scientific Foundation of the Spanish Association Against Cancer (hereinafter\, the Foundation) is to award grants to high-quality cancer research projects—both basic and translational—conducted under the supervision of a group leader. These projects must be carried out entirely in Spain and be aligned with the strategic areas of the Spanish Association Against Cancer (hereinafter\, the Association) and the needs of cancer patients. \n  \nThis call for proposals includes two categories: \n• Individual category: Collaborations with an associated budget are not permitted. Only the lead applicant may be listed in the proposal. If the proposal includes the participation of occasional collaborators without an associated budget\, it must be submitted under this category. \n• Collaborative mode: A maximum of three collaborators with an associated budget will be allowed to participate\, and they must conduct their research at Spanish institutions. The applicant will serve as the principal investigator for the proposal. \nIn all cases\, it is mandatory to include a description explaining why the project is of interest to the Association and to cancer patients. All aspects of the call for proposals will be managed through the Foundation’s grant management platform (Grant Management System)\, where you can find the relevant documentation. \n\n  \nRequirements\n Requirements for the applicant (proposal leader) \n• Hold a Ph.D. \n• Be contractually affiliated with a public or private nonprofit organization in Spain that is qualified to conduct scientific research. The project must be carried out at that organization\, which must be listed in the application. \n• Publications: o 2 research articles as first author or corresponding author\, published or accepted in peer-reviewed international journals in the first quartile (according to JCR or SJR indices) at the time of application. Publications dated after the application deadline will not be accepted. o Only original articles will be considered; reviews\, book chapters\, and patents are excluded. \n• Emerging groups are encouraged to review the AECC Lab call for proposals. \nResearch Center \n• For the purposes of this call for proposals\, a research center (hereinafter\, “Center”) is defined as any public or private nonprofit entity capable of conducting scientific research in Spain. Projects carried out in industrial research laboratories will not be accepted. Applications from research centers that receive donations from private companies will be accepted. \n  \nFeatures of the Assistance\nDuration \nThe grant will have a duration of 4 years from the start date indicated in the specific annex to the framework agreement governing the specific conditions of the grant awarded. However\, once the first two years have elapsed\, the Foundation will conduct a midterm review. In the event of a negative evaluation\, the grant may be terminated early\, at the Foundation’s sole discretion. \nFinancial Assistance \nThis grant has a maximum allocation that varies depending on the type: \n• General individual projects: up to a maximum of 400\,000 euros gross over 4 years\, at a maximum of 100\,000 euros gross per year. \n• General collaborative projects: up to a maximum of 600\,000 euros gross over 4 years\, at a rate of up to 150\,000 euros gross per year. \nIn both cases\, the eligible expenses are detailed in the Annex: Guide to Eligibility and Justification of Expenses\, available in the “Documentation” section of the call for proposals. \n  \n  \nSubmission of Applications\nApplicants may submit only one proposal for this call for proposals. If the same project is submitted by different applicants\, both applications will be rejected. \nIf the applicant is not selected\, he or she may reapply in future calls for proposals\, provided that relevant changes have been made to the submitted project or to the laboratory where the project will be carried out\, in accordance with the comments in the evaluation report. \nContent of the Applications \nApplicants must be registered on the GMS platform at https://grants-fundacioncientifica-aecc.smartsimple.ie/s_Login.jsp \n\n  \nApplication Deadline\nThe  \napplication period\n begins on November 12\, 2026\, and ends on December 10\, 2026\, at 3:00 p.m. (Peninsular time). \nThe system will not accept submissions after the application deadline\, and only those applications submitted within the application period will be evaluated. We recommend submitting applications well in advance to avoid any issues with the GMS platform. \n\n  \nComplete guidelines for the call for applications\nhttps://www.contraelcancer.es/sites/default/files/ayudas/2026-11/Bases_Proyectos_PROYECTOS%20GENERALES%20AECC_2027.pdf
URL:https://ibsal.es/en/evento/aecc-2027-call-for-general-projects/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20270122
DTSTAMP:20261116T101313Z
CREATED:20261116T095900Z
LAST-MODIFIED:20261116T101313Z
UID:10002493-1794441600-1800575999@ibsal.es
SUMMARY:AECC LAB Call for Proposals 2027
DESCRIPTION:Purpose and Objective\nThe purpose of this call for proposals from the Scientific Foundation of the Spanish Association Against Cancer is to support emerging research groups in consolidating their lines of research by awarding grants to high-quality cancer research projects conducted entirely in Spain. \nAll aspects of the call for proposals will be managed through the Foundation’s grant management platform (Grant Management System)\, where you can find the relevant documentation. \nEmerging group: \nAn emerging group is defined as one that meets the following conditions \no Length of time the research line has been active: has been conducting an independent line of research for less than 5 years. \no Formal recognition: Research staff are recognized as group leaders in the research center’s organizational chart. \no Calculation of the period: The 5-year period will be calculated up to the closing date of the call for applications. For the purposes of calculating this period\, the following extensions will apply: \n− Maternity\, childbirth\, adoption\, or foster care: 18 months for each child. \n− Paternity or parental leave: for the period actually taken. \n− Temporary disability due to illness: for the corresponding period. \nApplicants who wish to claim any of these circumstances must declare so when submitting their application. The Foundation may request the necessary supporting documentation to verify compliance with the eligibility requirements. \n  \nRequirements\n: Requirements for Applicants \n• Hold a Ph.D. \n• Be contractually affiliated with a public or private nonprofit organization in Spain that is qualified to conduct scientific research\, or have a commitment to be affiliated with such an organization at the time the grant begins. This organization must be the one where the project is carried out and the one listed in the application. \n• Be an independent group leader of an emerging group (see Definitions). To qualify\, you must: \nor Submit a sworn statement signed by the applicant attesting to compliance with the profile requirements\, including the date on which the applicant became an independent group leader. \no If applicable\, submit a letter signed by the center’s legal representative stating the commitment to provide the successful applicant with space and resources at the start of the grant. \nProposal Requirements \n• The research project must have a solid research foundation that supports the hypothesis presented in the proposal (studies ranging from basic and translational oncology to preclinical studies). \nResearch Center \n• For the purposes of this call for proposals\, a research center (hereinafter\, “Center”) is defined as any public or private nonprofit entity capable of conducting scientific research in Spain. Projects carried out in industrial research laboratories will not be accepted. Applications from research centers that receive donations from private companies will be accepted. \n\n  \nFeatures of the Assistance\nDuration \nThe grant will last for 4 years from the start date indicated in the specific annex to the framework agreement governing the specific terms and conditions of the grant. However\, once the first two years have elapsed\, the Foundation will conduct a midterm review. \nFinancial Assistance This grant has a maximum budget of 400\,000 euros gross\, at a rate of 100\,000 euros gross per year\, for the implementation of the project. The eligible expenses are detailed in the Annex: Guide to Eligibility and Justification of Expenses\, available in the documentation section of the call for proposals. \nThis includes patent registration and applications\, technical reports on patentability\, drafting of business plans\, reports to third parties related to the proper development of the project\, regulatory roadmaps\, licensing agreements\, etc. \nSubmission of Applications\nApplicants may submit only one proposal for this call for proposals. If the same project is submitted by different applicants\, both applications will be rejected. If the applicant is not awarded a grant\, they may reapply in future calls for proposals\, provided that relevant changes have been made to the submitted project or to the laboratory where the project will be carried out\, in accordance with the observations in their evaluation report. To this end\, the Foundation will retain the scientific reports of the submitted projects for 5 years to verify that new applications include substantial modifications. \nAll projects must comply with current legal regulations and applicable ethical principles. The use of artificial intelligence (AI) tools is permitted to assist with writing\, translation\, language refinement\, code generation or review\, structuring ideas\, and other tasks related to the preparation of the application. The applicant is responsible at all times for the final content submitted and must ensure its accuracy\, completeness\, and compliance with the call for proposals. Whenever possible\, it is recommended to disclose the use of such tools. \nApplicants must be registered on the GMS platform at https://grants-fundacioncientifica-aecc.smartsimple.ie/s_Login.jsp   \n  \nContent of the Applications \n  \nDeadline for submitting applications\nThe application period begins on November 12\, 2026\, and ends on January 21\, 2027\, at 3:00 p.m. (Peninsular time). The system will not accept submissions after the call’s closing date\, and only applications submitted within the application period will be evaluated. \nComplete call for proposals guidelines\nhttps://www.contraelcancer.es/sites/default/files/ayudas/2026-11/Bases_Proyectos_LAB%20AECC_2027.pdf
URL:https://ibsal.es/en/evento/aecc-lab-call-for-proposals-2027/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20270129
DTSTAMP:20261116T161933Z
CREATED:20261116T155752Z
LAST-MODIFIED:20261116T161933Z
UID:10002497-1794441600-1801180799@ibsal.es
SUMMARY:AECC 2027 Clinical Trials Call for Proposals
DESCRIPTION:Purpose and Objective\nThe purpose of this call for proposals from the Scientific Foundation of the Spanish Association Against Cancer (hereinafter\, the Foundation) is to award grants to multicenter clinical research projects—not sponsored by the pharmaceutical industry—that accelerate the translation of research findings for the benefit of patients and promote the development of innovative research to advance clinical practice. \nThrough this call for proposals\, the Foundation offers financial support to nonprofit healthcare organizations and institutions affiliated with or contracted by the National Health System—such as hospitals or primary care centers—where the research will be conducted. This call for proposals involves the AECC Patient Advocacy Program\, composed of cancer patients and their caregivers. All administration of the call will be conducted through the Foundation’s grant management platform (Grant Management System\, hereinafter the GMS platform)\, where you can find the relevant documentation. \n  \nRequirements\n Project Requirements \n• It must be multidisciplinary (clinical and translational research) and multicenter\, conducted in accordance with a single protocol. \n• It must address a clinical concern in one of the following areas: \no Phase II and III clinical trials\, including those involving licensed drugs. \nAnalysis of predictive biomarkers or other strategies for early diagnosis and/or prevention. \nor Innovative\, non-commercial clinical studies initiated by researchers or academic societies. \nor Innovative multidisciplinary clinical studies that evaluate a multimodal therapeutic/diagnostic strategy. \no Clinical studies on new surgical strategies\, new technologies\, or palliative care\, including comparisons of different therapeutic approaches. \no Studies focused on addressing recurrence and metastasis. • The research project must demonstrate a clear potential impact on patients and be supported by a solid foundation of preliminary data that substantiates the proposed hypotheses. \n• The project design must address an unmet clinical need\, demonstrate innovation\, and identify tangible benefits for patients. It must also foster the exchange of ideas between translational and clinical research and generate evidence that facilitates its implementation in clinical practice. \n• Projects that align with any of the following objectives will be eligible: \n— Advancing cancer treatments \n— Patient-centered care \n— Support for early detection and prevention \n— Collaborative research \n• Clinical studies must include the analysis of patients’ overall survival among their primary objectives. \n• The research project must justify the need for collaboration among the various hospitals. \n• The winning groups must be composed of personnel from different collaborating centers; however\, in duly justified cases\, they may be composed of personnel from a single center. \n• Depending on the nature of the study\, it will be viewed favorably if the proposal has a broad geographic reach nationwide\, including centers with a proven track record in promoting initiatives of this type. \n• In order to ensure global access to and the social impact of research\, submitted projects must include a commitment to: \no Ensure that funded developments are made available to society on terms that provide equitable access. \no Ensure that the prices of the resulting products are fair and set in a transparent manner. \no Promote the openness and sharing of the knowledge generated. In addition\, the Foundation may establish\, within the framework of each project\, specific conditions aimed at strengthening compliance with these principles. \n  \nRequirements for the applicant (group leader) and the sponsoring organization \n\nIn the research project\, the role of the sponsoring entity must be held exclusively by the managing entity of the applicant/coordinating institution (hereinafter\, the Center).\nThe group leader at the Center will serve as the scientific coordinator of the research project and will be responsible for submitting the proposal under this call for proposals.\nThe scientific coordinator must have a demonstrable research career and have completed a doctoral dissertation.\nThe Foundation will sign the framework agreement and the specific grant annex with the center with which the scientific coordinator has a contractual relationship. The scientific coordinator will be responsible for the scientific direction of the project and for communicating with the Foundation.\nThe scientific coordinator may submit an application for the financial assistance provided for in this call for proposals\, provided that the research activities are conducted at healthcare institutions\, public research organizations\, or other nonprofit research centers in Spain. Collaborations with international groups may be considered\, but such groups may not receive direct funding under this call for proposals.\n\n  \nRequirements for Participating Institutions and Partner Groups \n• Each participating center must: \n\nHave prior experience in clinical research in the field of cancer diagnosis and treatment\, preferably in the context of the subject of the action.\nHave prior accreditation to conduct clinical research (e.g.\, Good Clinical Practice\, GCP).\n\n• Any member of the research team(s) must have a formal civil service\, statutory\, or employment relationship with the applicant or implementing entities for at least the period between the application submission date and the final grant award decision. \n• Collaborating groups will be defined as those institutions necessary for the proper implementation of the project\, which may: \n\nHave an associated budget.\nAct exclusively as patient recruitment centers\, without an associated budget.\n\n• Partner groups may only receive a budget for one proposal. \nGrant Characteristics\nDuration \nThe grant will have a maximum duration of 5 years from the start date indicated in the specific annex to the framework agreement governing the specific conditions of the grant awarded. However\, once the first three years have elapsed\, the Foundation will conduct an interim review. \nIn the event of a negative evaluation\, the grant may be terminated early\, at the sole discretion of the Foundation. \nFinancial Assistance \nThis grant has a maximum budget of 1\,000\,000 euros\, distributed over 5 annual installments\, at a maximum of 200\,000 euros gross per year. The eligible expense categories are detailed in the Annex: Guide to Eligibility and Justification of Expenses\, available in the documentation section of the call for proposals. All budget items must be itemized in the 5-year  financial report .   \n  \nApplications\n Applicants may submit only one proposal for this call for proposals. If the same project is submitted by different applicants\, both applications will be rejected. If the applicant is not awarded a grant\, they may reapply in future calls for proposals\, provided that relevant changes have been made to the submitted project and/or the research team\, in accordance with the observations in their evaluation report. \nThe use of artificial intelligence (AI) tools is permitted to assist with writing\, translation\, language refinement\, code generation or review\, structuring ideas\, and other tasks related to the preparation of the application. The applicant is responsible at all times for the final content submitted and must ensure its accuracy\, completeness\, and compliance with the call for proposals. Whenever possible\, it is recommended to disclose the use of such tools. \n  \nApplication Requirements \nApplication Deadline\nThe application period begins on November 12\, 2026\, and ends on January 28\, 2027\, at 3:00 p.m. (Peninsular time). \nComplete application guidelines\nhttps://www.contraelcancer.es/sites/default/files/ayudas/2026-11/Bases_Proyectos_ESTUDIOS%20CL%C3%8DNICOS%20AECC_2027.pdf
URL:https://ibsal.es/en/evento/aecc-2027-clinical-trials-call-for-proposals/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20270205
DTSTAMP:20261116T163429Z
CREATED:20261116T162425Z
LAST-MODIFIED:20261116T163429Z
UID:10002499-1794441600-1801785599@ibsal.es
SUMMARY:AECC 2027 Grants for Preventive Biology and Medicine
DESCRIPTION:Purpose and Objectives of the Call\n for Proposals “\n” The objective of this call for proposals is to provide financial support from the Scientific Foundation of the Spanish Association Against Cancer (hereinafter\, the Foundation) to high-quality research projects focused on the biology and medicine of cancer prevention\, which are conducted entirely in Spain and are of interest to the Spanish Association Against Cancer (hereinafter\, the Association) and to cancer patients. \nAll matters related to the call for applications will be handled through the Foundation’s Grant Management System\, where all relevant documentation can be found. \n  \nRequirements\nThe principal investigator applying for this call for proposals must:\n— Hold a doctorate (PhD).\n— Be contractually affiliated with a public or private nonprofit organization accredited for scientific research in Spain. The research project must be carried out at that organization\, which must be specified in the application.\n— Have at least two research articles published or accepted for publication as the last author or corresponding author in an international peer-reviewed scientific journal ranked in the first quartile at the time of application. Publications dated after the application submission date will not be accepted. Only original research will be considered; reviews\, book chapters\, and patents will not be included. \n  \nCall for Proposals: Guidelines\n Proposals should focus on areas of research that deepen our understanding of the biology and medicine of cancer prevention. The goal is to understand the biological mechanisms and etiology of cancer in order to develop precision prevention interventions. Topics may include epidemiology\, risk factors\, incidence and its modification\, survival\, and cancer prevention strategies. Proposals must focus on early prevention. Proposals aimed at secondary or tertiary prevention fall outside the scope of this call for proposals. \nProposals must provide evidence and consider the long-term sustainability of the project\, including regulatory aspects that will facilitate its future implementation. In all cases\, a description must be provided explaining why the project is of interest to the Association and to cancer patients. \n  \nFeatures of the Grant\nDuration \nThe grant will be valid for 3 years from the date of signature of the specific annex to the framework agreement governing the specific terms and conditions of the grant. \n  \nFinancial Assistance \nThis grant provides a maximum of 300\,000 € over 3 years\, with a maximum of 100\,000 € per year for the implementation of the project. \nThe Foundation offers an additional €3\,000 on top of the total grant amount to cover any expenses related to the protection of research results. This includes patent registration and applications\, technical patentability reports\, drafting of business plans\, third-party reports related to the proper development of the project\, regulatory roadmaps\, licensing agreements\, etc. \n  \nSubmission of Applications\nApplicants must register on the GMS platform at https://grants-fundacioncientifica-aecc.smartsimple.ie/s_Login.jsp\nDocumentation will only be accepted through this channel; documentation submitted through any other channel will not be accepted. \n  \nApplication Deadline\nThe  \napplication\n period begins on November 12\, 2026\, and ends on February 4\, 2027\, at 3:00 p.m. (Peninsular time). \nComplete terms and conditions of the call for\napplications\nClick here
URL:https://ibsal.es/en/evento/aecc-2027-grants-for-preventive-biology-and-medicine/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20270205
DTSTAMP:20261116T165506Z
CREATED:20261116T164128Z
LAST-MODIFIED:20261116T165506Z
UID:10002501-1794441600-1801785599@ibsal.es
SUMMARY:AECC Innova 2027 Grants
DESCRIPTION:Purpose and Objectives of the Call for Proposals\n “\n” The primary objective of this call for proposals is to identify and support projects with scientific\, clinical\, and market potential\, providing the opportunity to develop ambitious proof-of-concept studies capable of strengthening previous research findings\, thereby facilitating the preclinical\, preclinical\, early clinical\, or pilot validation of innovative technologies for their development and commercialization. \n  \nRequirements\n: Requirements for Applicants \n\nHold a doctoral degree.\nMaintain a valid contractual relationship with the applying institution at the time of application submission and throughout the duration of the grant.\nProvide scientific and technical leadership for the proposed project\, serving as the person responsible for implementing the work plan and achieving the stated objectives. It is not necessary to head a research group.\nComply with the rules regarding compatible and incompatible activities established in this call for proposals. Requirements for the applying institution\nBe a public or private nonprofit entity qualified to conduct scientific research in Spain (hereinafter\, “Center”).\nHave a Knowledge Transfer Office (hereinafter\, KTO)\, Innovation Unit\, or equivalent structure responsible for managing innovation and the transfer of the Center’s research results.\nSubmit a single application per Center. If a Center has more than one candidate proposal\, the KTO or Innovation Unit must first conduct an internal selection process among them. • Consortia may not apply\, even if they are composed of two or more Centers.\nAcceptance of the Terms and Conditions of the Call for Proposals: Participation in this call for proposals implies the express acceptance of its terms and conditions by the applying institution and all individuals participating in the project\, who acknowledge them as valid and enforceable obligations.\n\n  \nRequirements for the Applying Institution \n\nBe a public or private nonprofit entity qualified to conduct scientific research in Spain (hereinafter\, “Center”).\nHave a Knowledge Transfer Office (hereinafter\, KTO)\, Innovation Unit\, or equivalent structure responsible for managing innovation and the transfer of the Center’s research results.\nSubmit a single application per Center. If a Center has more than one candidate proposal\, the KTO or Innovation Unit must first conduct an internal selection process among them.\nConsortia may not apply\, even if they are composed of two or more Centers.\nAcceptance of the Terms and Conditions of the Call for Proposals: Participation in this call for proposals implies the express acceptance of its terms and conditions by the applying institution and all individuals participating in the project\, who acknowledge them as valid and enforceable obligations.\n\n  \nProposal Requirements \n• Submit an R&D&I project in the field of cancer focused on functional validation\, preclinical/early-clinical trials\, or pilot studies of innovative technologies aimed at transferring results to clinical\, industrial\, and/or business settings\, with potential for commercialization and exploitation. \n• Demonstrate that the expected and/or demonstrable results of the project are\, at the time of application\, at least at Technology Readiness Level (TRL) 3\, as defined by the European Commission at any given time\, which can be found in the “Documentation” section of the call for proposals. \n• Demonstrate the potential of the results to generate new opportunities or improvements in various areas of cancer research (prevention\, early diagnosis\, and/or treatment) and across all types of cancer. Specifically\, projects conducted in the following areas are considered eligible: \no Development and validation of biomedical innovations in cancer: \n▪ New therapies\, including drugs\, advanced therapies\, and other innovative approaches. \n▪ New methods\, tools\, or biomarkers for the prevention\, early detection\, diagnosis\, prognosis\, or monitoring of the disease. \n▪ Biomedical technologies\, medical devices\, and medtech solutions with potential clinical applications. \n▪ Digital health and artificial intelligence solutions designed to improve research\, clinical decision-making\, and care for cancer patients. \nor Innovation for clinical practice and healthcare training: \n▪ Medical technologies (medtech) aimed at improving clinical\, diagnostic\, therapeutic\, or patient care procedures. \n▪ Tools for the education or training of healthcare professionals to facilitate the safe and effective adoption of innovations in oncology. \n▪ Solutions that help improve the quality of care\, the patient experience\, and the efficiency of clinical processes. \n• Among other activities\, projects may include experimental validation\, prototype development\, pilot studies\, the generation of evidence to support technology transfer\, feasibility analyses\, and other actions necessary to promote the commercialization and exploitation of the results. \n• Present a strategy for the protection\, transfer\, and commercialization of research results that is appropriate for the project’s stage of development. \n  \nIntellectual Property and Exploitation Requirements \n• Projects may be submitted in which the intellectual property rights\, industrial property rights\, or know-how involved are held by the participating Center on a joint ownership basis with other entities—whether for-profit or nonprofit—or with individuals\, both Spanish and foreign\, in accordance with the provisions of point 12 of the call for proposals. \n• The intellectual property rights (IPR) involved in the project may be subject to exploitation agreements—such as licensing agreements—with other Spanish or foreign entities\, whether for-profit or nonprofit. \n• The financial assistance covered by this call for proposals will be awarded solely to the selected institution. \n  \nFeatures of the Grant\nDuration \nThe grant will have a maximum duration of 2 years from the start date specified in the specific annex to the framework agreement that will govern the terms of the grant. \nHowever\, the research staff must carry out the project over the number of months ultimately specified in the Work Plan set forth in the Scientific Report. \nFinancial Assistance \nThe maximum total amount of the grant for the selected project is 180\,000 euros. \nThe amount of the grant will be determined by the Foundation\, based on the eligible costs justified in the application and depending on the specific needs and circumstances of each project. \n  \nSubmission of Applications\nApplicants must register on the GMS platform at https://grants-fundacioncientifica-aecc.smartsimple.ie/s_Login.jsp \nDocuments will only be accepted through this channel; documents submitted through any other channel will not be accepted. \n  \nApplication Deadline\nThe  \napplication\n period begins on November 12\, 2026\, and ends on February 4\, 2027\, at 3:00 p.m. (Peninsular time). \n  \nComplete guidelines for the call for applications\nhttps://www.contraelcancer.es/sites/default/files/ayudas/2026-11/Bases_Proyectos_AECC%20INNOVA_2027.pdf
URL:https://ibsal.es/en/evento/aecc-innova-2027-grants/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261116
DTEND;VALUE=DATE:20270122
DTSTAMP:20261111T134724Z
CREATED:20261111T133132Z
LAST-MODIFIED:20261111T134724Z
UID:10002473-1794787200-1800575999@ibsal.es
SUMMARY:PARTNERSHIP: Transforming Health and Care Systems (THCS)
DESCRIPTION:Characteristics\n The pre-announcement of the joint transnational call for proposals of the Transforming Health and Care Systems Partnership THCS JTC 2027 “Transforming the Health and Care Workforce for Sustainable and Resilient Systems” has been published. \nThis call for proposals seeks to fund projects that accelerate the adoption\, adaptation\, testing\, evaluation\, and scaling of evidence-based solutions to transform human resources in health and care systems. The primary focus is not on developing new technology from scratch. Proposals must build on existing knowledge\, tools\, frameworks\, initiatives\, or best practices and focus on their implementation\, transfer\, and scaling. The project must address the transformation of the health and social care workforce\, for example\, solutions aimed at improving the systems’ capacity to\, among other things\, attract professionals\, train and develop staff\, allocate human resources appropriately\, retain professionals\, increase workforce resilience\, and facilitate the transition toward more population-oriented care. \nThe call for proposals is co-funded by the European Union\, with the Carlos III Health Institute (ISCIII) serving as the national funding agency. \nRequirements\n Four main types of participants are considered: \n\nAcademy\n Universities\, universities of applied sciences\, research centers\, higher education institutions\, etc.\nClinical/public health sector\n Hospitals\, polyclinics\, health centers\, public health organizations\, and other healthcare providers.\nCompanies\n Private companies of any size.\nOperational stakeholders\n Patient organizations\, citizens\, local communities\, schools\, municipalities\, NGOs\, consumer organizations\, etc. These actors should contribute useful knowledge\, promote the applicability of research\, or contribute to decision-making/organizational change.\n\n  \nAmong the requirements for forming a consortium\, the following must be taken into account: \n\nA minimum of 3 eligible partners from 3 different countries whose funding agencies are participating in the call for proposals.\nAt least 2 partners must be legal entities from two different EU Member States or countries associated with Horizon Europe.\nAll partners applying for funding must be legal entities independent of one another.\nA maximum of 9 funded partners per consortium and a maximum of 2 funded partners from the same country.\nThe coordinator must be eligible to receive funding from one of the participating national/regional funding agencies.\nUp to 2 self-funded collaborators are allowed; this limit may increase to 3 if one or more of the collaborators is an operational stakeholder\n\n\nSubmission deadline.\nThe following table lists the various dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 16\, 2026\n\n\nDeadline for Pre-Proposals\nJanuary 21\, 2027\, (2:00 p.m. CET)\n\n\nCall for Full Proposals\nStarting May 11\, 2026\n\n\nDeadline for full proposals\nJune 24\, 2027\, (2:00 p.m. CET)\n\n\nRebuttal stage\nSeptember 2027\n\n\nNotification of Funding Decisions\nOctober–November 2027\n\n\n\n  \n 
URL:https://ibsal.es/en/evento/partnership-transforming-health-and-care-systems-thcs-2/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261117
DTEND;VALUE=DATE:20261125
DTSTAMP:20261113T104924Z
CREATED:20261111T142338Z
LAST-MODIFIED:20261113T104924Z
UID:10002476-1794873600-1795564799@ibsal.es
SUMMARY:Data Protection in Biomedical Research
DESCRIPTION:In-Person Course: “Data Protection in Biomedical Research“ \nObjective: \nTo train professionals to understand and correctly apply data protection regulations and principles in the field of biomedical research. \nSpecific Objectives: \nTo identify the fundamental principles and obligations of the regulations \nDistinguish between the main categories of data and understand their protection regime \nUnderstand the legal bases that allow for data processing in research \nCorrectly apply the requirements regarding consent\, information\, and the exercise of rights \nIdentify the responsibilities of all stakeholders \nDate \nNovember 17\, 19\, and 24\, 2026 \nLocation \n\, S. Medical Day Hospital\, BL.B\, PL.0 \nProgram: \n\n\n\nDate / Time\nLocation\nSpeaker\nContent\n\n\n\n11/17/26\nS. DAY HOSPITAL\, MEDICO BLOCK B\, FLOOR 0\n– ENRIQUE NIETO MANIBARDO\n– INTRODUCTION TO DATA PROTECTION AND GENERAL FRAMEWORK\n\n\n\n16:00 / 19:30\n\n\n\n– PERSONAL HEALTH  INFORMATION \n\n\n\n– LEGAL BASIS FOR THE PROCESSING OF PERSONAL DATA\n\n\n\n11/19/26\nS. MEDICAL DAY HOSPITAL\, BLOCK B\, FLOOR 0\n– ENRIQUE NIETO MANIBARDO\n– ROLES OF THE PARTIES INVOLVED IN THE RESEARCH: SPONSOR\, INVESTIGATOR\, CENTER\, MONITOR\, ETC.\n\n\n\n16:00 / 19:00\n\n\n\n– PRINCIPLES OF PERSONAL DATA PROCESSING\n\n\n\n– CITIZENS’  RIGHTS : INFORMATION\,         TRANSPARENCY          AND CONSENT\n\n\n\n– RETENTION AND DELETION OF HEALTH-RELATED DATA\n\n\n\n11/24/26\nS. MEDICAL DAY HOSPITAL\, BLOCK B\, FLOOR 0\n– ENRIQUE NIETO MANIBARDO\n– ACCESS TO MEDICAL RECORDS \n– EIPD \, SECURITY MEASURES\, AND SECURITY BREACHES\n\n\n\n16:00 / 19:30\n\n\n\n– ANONYMIZATION \,     PSEUDONYMIZATION      AND DATA ENCRYPTION\n\n\n\n– REFERENCE TO THE SPECIAL REGULATORY FRAMEWORK FOR HEALTHCARE AND DATA PROTECTION\n\n\n\n\nRegistration:  \nThe registration deadline is Monday\, November 16\, 2026. Please register individually through our website. \nPrice: \n0 euros. \nSelection process: \nEnrollment in the course will be on a first-come\, first-served basis\, as agreed by the IBSAL Training Committee\, with 10 spots reserved for IBSAL staff. \nTo successfully complete the course and receive the corresponding certificate\, participants must attend at least 80% of the total course sessions.
URL:https://ibsal.es/en/evento/data-protection-in-biomedical-research/
CATEGORIES:Sacyl Course
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261118
DTEND;VALUE=DATE:20270202
DTSTAMP:20261112T075331Z
CREATED:20261111T141633Z
LAST-MODIFIED:20261112T075331Z
UID:10002479-1794960000-1801526399@ibsal.es
SUMMARY:PARTNERSHIP European Partnership on One Health Antimicrobial Resistance (OH AMR)
DESCRIPTION:Characteristics\n The official pre-announcement for the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR JTC 2027)\, entitled “Understand\, Model and Stop AMR Transmission\,” has been published. This call for proposals is highly focused on the One Health approach and not exclusively on clinical practice. The overall objective is to improve the understanding of the mechanisms of emergence\, evolution\, selection\, persistence\, and transmission of antimicrobial resistance (AMR) and to develop strategies to prevent its emergence and spread. \nThe call for proposals is organized into three main categories: \nTopic 1 – Model of AMR Transmission Dynamics \nDevelopment of models of AMR transmission dynamics for: \n\npredict the risk of the emergence and spread of resistance;\nbetter understand the mechanisms of transmission;\nprovide evidence to aid decision-making by public authorities.\n\n  \nTopic 2 – Host commensal microorganisms \nStudy and characterize the role of host commensal microorganisms\, including fungi\, in the dynamics of AMR. Solutions may also be developed for the selective decolonization of resistant organisms in humans and animals to prevent transmission. \nTopic 3 – Environmental hotspots \nDevelop or improve tools\, methods\, and strategies to reduce resistant bacteria and fungi and resistance genes in environmentalhotspots\, as well as study the impact of these measures on the transmission of AMR. \nThis call for proposals is co-funded by the European Union and involves 33 funding organizations from 26 countries\, with an estimated total budget of 28 million euros. \nIn addition\, the Carlos III Health Institute (ISCIII) is participating in this call as a national funding agency. \nRequirements\nThis call for proposals will fund only transnational research and innovation projects. \nThe consortium must comply with the following: \n\nAt least 3 eligible partners must apply for funding.\nAll three must be from three different eligible countries.\nAt least 2 of those countries must be EU Member States or associated countries.\nA maximum of 6 partners in the consortium\, including non-funded partners. The maximum may be increased to 7 partners if at least one of the following conditions is met:\n\nparticipation of a partner from an under-represented country;\nparticipation of an Early-Career Researcher (ECR) as Principal Investigator;\nparticipation of a startup\, SME\, or company/industry.\n\n\n\n\n\n\n  \nIn addition to the characteristics specific to European Partnerships: \n\nA maximum of two partners may apply for funding from the same funding agency.\nA Principal Investigator may participate in a maximum of two proposals: one as coordinator and one as a partner.\nEach participant must also comply with the national/regional eligibility rules of their funding agency.\n\nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 18\, 2026\n\n\nDeadline for Pre-Proposals\nFebruary 1\, 2027\, (2:00 p.m. CET)\n\n\nNotification of the results of the pre-proposal\nApril 2027\n\n\nDeadline for full proposals\nJune 23\, 2027\, (2:00 p.m. CET)\n\n\nRebuttal stage\nTBA\, 2027\n\n\nNotification of Funding Decisions\nTBA\, 2027\n\n\n\n  \n 
URL:https://ibsal.es/en/evento/partnership-european-partnership-on-one-health-antimicrobial-resistance-oh-amr/
CATEGORIES:Calls for research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
DTSTAMP:20261026T105315Z
CREATED:20261026T105314Z
LAST-MODIFIED:20261026T105315Z
UID:10002368-1795478400-1795564799@ibsal.es
SUMMARY:Human Exome Sequencing and Analysis
DESCRIPTION:In-Person Course: “Human Exome Sequencing and Analysis”   “ \n  \nObjective: \nThe overall objective of this course is for students to acquire a basic understanding of the sequencing and bioinformatic analysis of human exomes. \n  \nSpecific objectives: \nUnderstand the main high-throughput sequencing techniques. \n– Recognize and use general-purpose databases in the field of exome sequencing. \n– Access information from public exome data repositories \n– Perform bioinformatic analyses of exomes using web-based tools. \n  \nDate \nTuesday\, November 24\, 2026\, from 9:00 a.m. to 3:00 p.m. \nLocation \nSequencing Service. R&D&I Building\, 2 Espejo St. November 24\, 2026\, 9:00 a.m.–11:00 a.m.\nComputer Lab. School of Nursing. Miguel de Unamuno Campus. November 24\, 2026\, from 11:00 a.m. to 3:00 p.m.      \nProgram: \n\n\n\nCourse Date\nSchedule\nContent\nFirst Name\, Last Name\, and Qualification of the INSTRUCTOR\n\n\nNovember 24\, 2026 \n\n9:00 a.m. – 10:00 a.m.\nIntroduction to Mass Sequencing.\nMaría Jara Acebedo. \nPh.D. in molecular biology and head of the High-Throughput Sequencing Service at USAL.\n\n\nNovember 24\, 2026\n10:00 a.m. – 11:00 a.m.\nTour of the Mass Sequencing Laboratory.\nMaría Jara Acebedo. \nPh.D. in molecular biology and head of the Mass Sequencing Service at USAL.\n\n\nNovember 24\, 2026\n11:00 a.m. – 12:00 p.m.\nBioinformatics Applications and Resources in Genomics.\nCarlos Prieto Sánchez. \nPh.D. in Bioinformatics and Head of the Bioinformatics Service at USAL.\n\n\nNovember 24\, 2026\n12:00 – 12:30\nAccess to Experimental Genomics Data. \n\nCarlos Prieto Sánchez. \nPh.D. in Bioinformatics and head of the Bioinformatics Service at USAL.\n\n\nNovember 24\, 2026\n12:30 p.m. – 3:00 p.m.\nExome Analysis with MutationMining \n\nCarlos Prieto Sánchez. \nPh.D. in Bioinformatics and Head of the Bioinformatics Service at USAL.\n\n\n\nTwo-hour practice session \nEnrollment:   \nREGISTRATION: \nThe registration deadline is Friday\, November 20\, 2026. Please register individually through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \nPrice: \n0 euros. \nMethod of selection: \nEnrollment in the course will be on a first-come\, first-served basis\, in accordance with the decision of the IBSAL Training Committee; 15 spots are reserved for IBSAL staff.
URL:https://ibsal.es/en/evento/human-exome-sequencing-and-analysis/
CATEGORIES:IBSAL Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20261124T083000
DTEND;TZID=UTC:20261124T093000
DTSTAMP:20261113T111553Z
CREATED:20261113T111553Z
LAST-MODIFIED:20261113T111553Z
UID:10002487-1795509000-1795512600@ibsal.es
SUMMARY:PREDOC Seminar: Development of polysaccharide-based multiparticle systems for the release of tyrosine kinase inhibitor drugs in the colon
DESCRIPTION:Speaker: Juan Pablo Sánchez Pérez. APSF-02 – Experimental and Clinical Pharmacokinetics \nDate: Tuesday\, November 24\, 2026\nTime: 8:30–9:30 a.m.\nLocation: Graduation Hall\, School of Medicine\, University of Salamanca \n\n 
URL:https://ibsal.es/en/evento/predoc-seminar-development-of-polysaccharide-based-multiparticle-systems-for-the-release-of-tyrosine-kinase-inhibitor-drugs-in-the-colon/
LOCATION:Hall of Degrees. Faculty of Medicine of the University of Salamanca.\, C. Alfonso X el Sabio\, s/n\, Salamanca\, Salamanca\, 37007\, Spain
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://ibsal.es/wp-content/uploads/2026/11/Seminario-predoc-24.11.2026.png
END:VEVENT
END:VCALENDAR